isoxazoles has been researched along with teriflunomide in 122 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 33 (27.05) | 18.2507 |
| 2000's | 49 (40.16) | 29.6817 |
| 2010's | 38 (31.15) | 24.3611 |
| 2020's | 2 (1.64) | 2.80 |
| Authors | Studies |
|---|---|
| Braatz-Trulson, J; Greene, S; Lou, L; Watanabe, K | 1 |
| Dias, VC; LeGatt, DF; Lucien, J; Yatscoff, RW | 2 |
| Cao, W; Huang, X; Morris, RE; Shorthouse, RA; Zheng, B | 1 |
| Jeske, S; Schlotte, V; Weithmann, KU | 1 |
| Fang, J; Ju, DW; Wang, HB; Zheng, QY | 2 |
| Bartlett, R; Bremer, EG; Finnegan, A; Kochhar, K; Mattar, T | 1 |
| Bartlett, RR; Müller, HJ; Zielinski, T | 1 |
| Cain, GA; Copeland, RA; Davis, JP; Magolda, RL; Pitts, WJ | 1 |
| Cao, W; Morris, RE; Nair, RV | 2 |
| Morris, RE; Shorthouse, R; Silva, HT | 1 |
| Morris, RE; Silva Júnior, HT | 1 |
| Blinder, L; Chong, AS; Finnegan, A; Gong, H; Shen, J; Williams, JW; Xu, X | 1 |
| Aquino, M; Bertolini, G; Biffi, M; d'Atri, G; Di Pierro, F; Ferrario, F; Leoni, F; Mascagni, P; Somenzi, F; Zaliani, A | 1 |
| Ekberg, H; Qi, Z | 1 |
| Bartlett, RR; Dimitrijevic, M; Stosic-Grujicic, S | 1 |
| Cannon, A; DeManvelle, T; Gregory, CR; Harb, M; Morris, RE; Ortega, T; Stewart, A; Sturges, B | 1 |
| Amano, Y; Kitagawa, H; Mizushima, Y; Ogata, K | 1 |
| Aggarwal, BB; Manna, SK | 1 |
| Berry, GJ; Boeke, K; Christians, U; Gummert, JF; Hausen, B; Morris, RE | 1 |
| Abts, HF; Homey, B; Köhrer, K; Michel, G; Mirmohammadsadegh, A; Ruzicka, T | 1 |
| Badii, M | 1 |
| Morris, RE; Sherwood, SW; Silva, HT; Slauson, SD | 1 |
| Blinder, L; Chong, AS; Clardy, C; Foster, P; Huang, W; Liu, W; Luo, J; Ma, L; Shen, J; Williams, JA; Xiao, F; Xu, W; Xu, X | 1 |
| Hamilton, LC; Vojnovic, I; Warner, TD | 1 |
| Blinder, L; Chong, AS; Huang, W; Mall, JW; Myers, JA; Saclarides, TJ; Shen, J; Williams, JW; Xu, X | 1 |
| Dax, CI; Kirschbaum, B; Mangold, U; Müllner, S; Saar, K; Schwab, W | 1 |
| Bartlett, RR; Kurrle, R; Schleyerbach, R; Schorlemmer, HU | 2 |
| Bartlett, RR; Haun, G; Milbert, U; Schorlemmer, HU; Wunschel, M; Zeitter, D | 1 |
| Czech, J; Kurrle, R; Schorlemmer, HU | 1 |
| Clardy, J; Grossman, TH; Liu, S; Neidhardt, EA; Ocain, T | 1 |
| Jankovic, V; Popadic, D; Samardzic, T; Stosic-Grujicic, S; Trajkovic, V | 1 |
| Schattenkirchner, M | 1 |
| Breedveld, FC; de Koster, BM; Elferink, JG; Kraan, MC; Post, WJ; Tak, PP | 1 |
| Grossman, TH; Hedstrom, L; McLean, JE; Neidhardt, EA | 1 |
| Colic, M; Dimitrijevic, M; Jandric, D; Popovic, P; Stojic Vukanic, Z | 1 |
| Albert, R; Andersen, E; Floersheim, P; Hungerford, V; Papageorgiou, C; Schreier, MH; Zurini, M | 1 |
| Colic, M; Dimitrijevic, M; Popovic, P; Vucevic, D | 1 |
| Schorlemmer, HU | 1 |
| Hossain, MM; Margolis, DM | 1 |
| Jin, Y; Li, CY; Li, J; Li, YH; Xu, SY; Yao, HW; Zhang, YF | 1 |
| Collins, M; Graves, LM; Huang, M; Mitchell, BS; Wang, Y | 1 |
| Drakulic, D; Miljkovic, Dj; Samardzic, T; Stosic-Grujicic, S; Trajkovic, V | 1 |
| Kim, TH; Löffler, M; Na, HS | 1 |
| Brune, K; Gillich, M; Hinz, B; Schmidt, A; Schwind, B | 1 |
| Dalvie, DK; Doan, A; Kalgutkar, AS; McLeod, DG; Murray, JC; Nguyen, HT; Vaz, AD | 1 |
| Breedveld, FC; Dijkmans, BA; Kraan, MC; Smeets, TJ; Tak, PP; van Loon, MJ | 1 |
| Burger, D; Dayer, JM; Gabay, C; Guerne, PA; Magne, D; Mezin, F; Palmer, G | 1 |
| Chen, JQ; Li, J; Xu, SY; Yao, HW | 3 |
| Arai, Y; Hakeda, Y; Kaneda, T; Kobayashi, Y; Kumegawa, M; Sato, T; Shin, K; Ueyama, S; Yoshida, Y | 1 |
| Brouwers, JR; Houtman, PM; Jansen, TL; Janssen, M; Keuper, R; van de Laar, MA; van Roon, EN; Yska, JP | 1 |
| Brouwers, JR; Jansen, TL; Raemaekers, J; van Roon, EN; van Wanrooy, M; Yska, JP | 1 |
| Atwood, W; Foster, P; Garfinkel, M; Gillen, D; Harland, R; Javaid, B; Josephson, MA; Kadambi, PV; Meehan, SM; Millis, JM; Thistlewaite, JR; Williams, JW | 1 |
| Grisar, J; Hörl, WH; Kirsch, BM; Säemann, MD; Smolen, JS; Stuhlmeier, K; Stulnig, TM; Watschinger, B; Zeyda, M; Zlabinger, GJ | 1 |
| Beneytout, JL; Bertin, P; Léger, DY; Liagre, B; Trèves, R; Vergne-Salle, P | 1 |
| Chan, V; Charles, BG; Tett, SE | 1 |
| Geyeregger, R; Hörl, WH; Poglitsch, M; Säemann, MD; Smolen, JS; Stulnig, TM; Waldhäusl, W; Zeyda, M; Zlabinger, GJ | 1 |
| Atwood, W; Foster, P; Garfinkel, M; Gillen, D; Harland, R; Javaid, B; Jordan, J; Josephson, MA; Kadambi, P; Meehan, S; Millis, MJ; Sadhu, M; Thistlethwaite, RJ; Williams, J | 1 |
| Beerheide, W; Boelsterli, UA; Latchoumycandane, C; Sattabongkot, J; Seah, QM; Tan, RC | 1 |
| Guerne, PA; Magne, D; Mézin, F; Palmer, G | 1 |
| Bijlsma, JW; Geenen, R; Goldschmeding, R; Kruize, AA; van Roon, EN; van Roon, JA; van Woerkom, JM; Verstappen, SM | 1 |
| Jin, Y; Li, J; Lü, XW; Si, HF | 1 |
| Chen, FP; Davis, IC; Hickman-Davis, JM; Lazarowski, ER; Matalon, S; Sullender, WM | 1 |
| Chen, YJ; Gregory, CR; Kyles, AE; Lindsay, LL; MacLeod, JS; Mehl, M; Poland, AM; Sykes, JE; Waldman, WJ; Williams, CR | 1 |
| Bogner, C; Decker, T; Oelsner, M; Peschel, C; Ringshausen, I | 1 |
| Nakayamada, S; Ra, C; Saito, K; Sawamukai, N; Tanaka, Y; Yamaoka, K | 1 |
| Guo, A; Jiang, H; Li, J; Lü, X; Si, HF | 1 |
| Guo, A; Jiang, H; Li, J; Lv, X; Si, HF | 1 |
| Herédi-Szabó, K; Jani, M; Jánossy, J; Kis, E; Krajcsi, P; Molnár, E; Nagy, T; Német, K; Ujhellyi, O | 1 |
| Bian, F; Hao, N; Zhang, M | 1 |
| Buist-Homan, M; Faber, KN; Kalsbeek, AJ; Moshage, H; Vrenken, TE | 1 |
| Arimura, A; Deguchi, M; Furue, Y; Hattori, M; Hirano, Y; Hojou, K; Iguchi, M; Kishino, J; Mochizuki, I; Nagira, M; Nishitani, Y; Okazaki, K; Yamamoto, M; Yasui, K | 1 |
| Chan, EC; New, LS | 1 |
| Boelsterli, UA; Chan, EC; New, LS; Seah, QM | 1 |
| Li, J; Tang, X; Yang, J | 1 |
| Bohanec Grabar, P; Dolzan, V; Grabnar, I; Logar, D; Mrhar, A; Peterlin Masic, L; Rozman, B; Suput, D; Tomsic, M; Trdan, T | 1 |
| Inokuma, S; Matsuda, T; Otsuka, T; Saeki, Y; Sagawa, A; Sato, T; Sawada, T; Takemura, T; Takeuchi, T | 1 |
| Bernhoff, E; Gutteberg, TJ; Hirsch, HH; Kjerpeseth, LJ; Rinaldo, CH; Tylden, GD | 1 |
| Chen, H; Cook, MR; Jaskula-Sztul, R; Kunnimalaiyaan, M; Luo, J; Pinchot, SN | 1 |
| Garrett, DA; Liu, DP; Rainey, PM; Sobhani, K | 1 |
| Brizzolara, R; Clerico, P; Cutolo, M; Meroni, M; Molfetta, L; Montagna, P; Seriolo, B; Soldano, S; Sulli, A; Triolo, P; Villaggio, B | 1 |
| Parekh, JM; Sanyal, M; Shrivastav, PS; Sutariya, DK; Vaghela, RN; Yadav, M | 1 |
| Joo, HJ; Kim, KA; Park, JY | 1 |
| Greenhaw, J; Salminen, WF; Shi, Q; Yang, X | 1 |
| Li, RS; Qiao, X; Yu, WM; Yuan, YC | 1 |
| Chen, YJ; Craigmill, A; Gregory, CR; Kyles, AE; Mehl, ML; Tell, L | 1 |
| Gu, JR; Huang, JL; Wang, MX; Wu, SY; Xie, XJ; Zhu, S | 1 |
| Cohn, LA; Papich, MG; Reinero, CR; Singer, LM | 1 |
| Diamond, MI; Fuentealba, RA; Marasa, J; Piwnica-Worms, D; Weihl, CC | 1 |
| Dietrich, S; Dreger, P; Giese, T; Hahn, E; Hess, M; Ho, AD; Hüllein, J; Krämer, OH; Luft, T; Rieger, M; Schäfer, C; Tretter, T; Zenz, T | 1 |
| Agarwal, S; Chattaraj, TK; Das, A; Ghosh, D; Pal, TK; Sarkar, AK | 1 |
| Baliga, P; Bratton, C; Chavin, K; Krisl, JC; McGillicuddy, J; Pilch, N; Taber, DJ; Thomas, B | 1 |
| Abrahams, AC; de Bruin, M; Hubeek, I; Kemperman, H | 1 |
| Jang, HS; Kerkvliet, NI; Koch, DC; Kolluri, SK; Kopparapu, PR; O'Donnell, EF; Phillips, JL; Tanguay, RL | 1 |
| Bergner, R; Löffler, C; Peters, L; Schmitt, V | 1 |
| O'Doherty, C; Polasek, TM; Rowland, A; Sorich, MJ; Wiese, MD | 1 |
| Kim, EY; Kim, HS; Lim, YJ; Moon, BS; Oh, M; Shim, EJ; Shin, JG; Shon, JH; Song, GS | 1 |
| Chen, B; Huang, WH; Lee, AR; Palfey, B; Shaw, J; Song, Y; Zhang, Y | 1 |
| Dodam, JR; Nafe, LA; Reinero, CR | 1 |
| Bogachkov, Y; Doscas, ME; Kaufman, H; Li, Y; Rao, GS; Ruby, C; Usha, L; Wang, Y; Williams, JW; Williamson, AJ; Xiao, F; Xu, X; Zhou, J | 1 |
| Brooks, JB; Fragoso, YD | 1 |
| Bernard, MK; Czaja, K; Drabińska, B; Jodłowska, E; Kujawski, J | 1 |
| Bae, J; Park, JW | 1 |
| Dong, GF; He, DN; Li, L; Zhang, GF; Zhang, X | 1 |
| Foster, DJ; Hopkins, AM; O'Doherty, CE; Proudman, SM; Upton, RN; Wiese, MD | 1 |
| Bencsik, K; Rózsa, C; Vécsei, L | 1 |
| Johnson-Davis, KL; Rockwood, AL; Rule, GS | 1 |
| Cao, YY; Chen, C; Lin, YF; Luan, Y; Ma, LL; Ni, X; Pan, GY; Wang, J; Wang, L; Wu, ZT; Zhang, XF | 1 |
| Gangopadhyay, D; Mishra, H; Mishra, PC; Sharma, P; Singh, RK | 1 |
| Barmbalexis, P; Bikiaris, DN; Siafaka, PI | 1 |
| Aly, L; Hemmer, B; Korn, T | 1 |
| Cho, ML; Jhun, JY; Kim, EK; Lee, HJ; Lee, WS; Min, JK; Moon, SJ; Park, SH | 1 |
| Barlow, EA; Bilger, A; Bristol, JA; Delecluse, HJ; Kenney, SC; Li, Z; Ma, S; Nawandar, D; Plowshay, J; Romero-Masters, JC; Tsai, MH | 1 |
| Jiang, L; Jiang, M; Li, W; Ling, C; Zhang, W | 1 |
| Abbasi, S; Abd El-Wahab, A; Abdallah, M; Abebe, G; Aca-Aca, G; Adama, S; Adefegha, SA; Adidigue-Ndiome, R; Adiseshaiah, P; Adrario, E; Aghajanian, C; Agnese, W; Ahmad, A; Ahmad, I; Ahmed, MFE; Akcay, OF; Akinmoladun, AC; Akutagawa, T; Alakavuklar, MA; Álava-Rabasa, S; Albaladejo-Florín, MJ; Alexandra, AJE; Alfawares, R; Alferiev, IS; Alghamdi, HS; Ali, I; Allard, B; Allen, JD; Almada, E; Alobaid, A; Alonso, GL; Alqahtani, YS; Alqarawi, W; Alsaleh, H; Alyami, BA; Amaral, BPD; Amaro, JT; Amin, SAW; Amodio, E; Amoo, ZA; Andia Biraro, I; Angiolella, L; Anheyer, D; Anlay, DZ; Annex, BH; Antonio-Aguirre, B; Apple, S; Arbuznikov, AV; Arinsoy, T; Armstrong, DK; Ash, S; Aslam, M; Asrie, F; Astur, DC; Atzrodt, J; Au, DW; Aucoin, M; Auerbach, EJ; Azarian, S; Ba, D; Bai, Z; Baisch, PRM; Balkissou, AD; Baltzopoulos, V; Banaszewski, M; Banerjee, S; Bao, Y; Baradwan, A; Barandika, JF; Barger, PM; Barion, MRL; Barrett, CD; Basudan, AM; Baur, LE; Baz-Rodríguez, SA; Beamer, P; Beaulant, A; Becker, DF; Beckers, C; Bedel, J; Bedlack, R; Bermúdez de Castro, JM; Berry, JD; Berthier, C; Bhattacharya, D; Biadgo, B; Bianco, G; Bianco, M; Bibi, S; Bigliardi, AP; Billheimer, D; Birnie, DH; Biswas, K; Blair, HC; Bognetti, P; Bolan, PJ; Bolla, JR; Bolze, A; Bonnaillie, P; Borlimi, R; Bórquez, J; Bottari, NB; Boulleys-Nana, JR; Brighetti, G; Brodeur, GM; Budnyak, T; Budnyk, S; Bukirwa, VD; Bulman, DM; Burm, R; Busman-Sahay, K; Butcher, TW; Cai, C; Cai, H; Cai, L; Cairati, M; Calvano, CD; Camacho-Ordóñez, A; Camela, E; Cameron, T; Campbell, BS; Cansian, RL; Cao, Y; Caporale, AS; Carciofi, AC; Cardozo, V; Carè, J; Carlos, AF; Carozza, R; Carroll, CJW; Carsetti, A; Carubelli, V; Casarotta, E; Casas, M; Caselli, G; Castillo-Lora, J; Cataldi, TRI; Cavalcante, ELB; Cavaleiro, A; Cayci, Z; Cebrián-Tarancón, C; Cedrone, E; Cella, D; Cereda, C; Ceretti, A; Ceroni, M; Cha, YH; Chai, X; Chang, EF; Chang, TS; Chanteux, H; Chao, M; Chaplin, BP; Chaturvedi, S; Chaturvedi, V; Chaudhary, DK; Chen, A; Chen, C; Chen, HY; Chen, J; Chen, JJ; Chen, K; Chen, L; Chen, Q; Chen, R; Chen, SY; Chen, TY; Chen, WM; Chen, X; Chen, Y; Cheng, G; Cheng, GJ; Cheng, J; Cheng, YH; Cheon, HG; Chew, KW; Chhoker, S; Chiu, WN; Choi, ES; Choi, MJ; Choi, SD; Chokshi, S; Chorny, M; Chu, KI; Chu, WJ; Church, AL; Cirrincione, A; Clamp, AR; Cleff, MB; Cohen, M; Coleman, RL; Collins, SL; Colombo, N; Conduit, N; Cong, WL; Connelly, MA; Connor, J; Cooley, K; Correa Ramos Leal, I; Cose, S; Costantino, C; Cottrell, M; Cui, L; Cundall, J; Cutaia, C; Cutler, CW; Cuypers, ML; da Silva Júnior, FMR; Dahal, RH; Damiani, E; Damtie, D; Dan-Li, W; Dang, Z; Dasa, SSK; Davin, A; Davis, DR; de Andrade, CM; de Jong, PL; de Oliveira, D; de Paula Dorigam, JC; Dean, A; Deepa, M; Delatour, C; Dell'Aiera, S; Delley, MF; den Boer, RB; Deng, L; Deng, Q; Depner, RM; Derdau, V; Derici, U; DeSantis, AJ; Desmarini, D; Diffo-Sonkoue, L; Divizia, M; Djenabou, A; Djordjevic, JT; Dobrovolskaia, MA; Domizi, R; Donati, A; Dong, Y; Dos Santos, M; Dos Santos, MP; Douglas, RG; Duarte, PF; Dullaart, RPF; Duscha, BD; Edwards, LA; Edwards, TE; Eichenwald, EC; El-Baba, TJ; Elashiry, M; Elashiry, MM; Elashry, SH; Elliott, A; Elsayed, R; Emerson, MS; Emmanuel, YO; Emory, TH; Endale-Mangamba, LM; Enten, GA; Estefanía-Fernández, K; Estes, JD; Estrada-Mena, FJ; Evans, S; Ezra, L; Faria de, RO; Farraj, AK; Favre, C; Feng, B; Feng, J; Feng, L; Feng, W; Feng, X; Feng, Z; Fernandes, CLF; Fernández-Cuadros, ME; Fernie, AR; Ferrari, D; Florindo, PR; Fong, PC; Fontes, EPB; Fontinha, D; Fornari, VJ; Fox, NP; Fu, Q; Fujitaka, Y; Fukuhara, K; Fumeaux, T; Fuqua, C; Fustinoni, S; Gabbanelli, V; Gaikwad, S; Gall, ET; Galli, A; Gancedo, MA; Gandhi, MM; Gao, D; Gao, K; Gao, M; Gao, Q; Gao, X; Gao, Y; Gaponenko, V; Garber, A; Garcia, EM; García-Campos, C; García-Donas, J; García-Pérez, AL; Gasparri, F; Ge, C; Ge, D; Ge, JB; Ge, X; George, I; George, LA; Germani, G; Ghassemi Tabrizi, S; Gibon, Y; Gillent, E; Gillies, RS; Gilmour, MI; Goble, S; Goh, JC; Goiri, F; Goldfinger, LE; Golian, M; Gómez, MA; Gonçalves, J; Góngora-García, OR; Gonul, I; González, MA; Govers, TM; Grant, PC; Gray, EH; Gray, JE; Green, MS; Greenwald, I; Gregory, MJ; Gretzke, D; Griffin-Nolan, RJ; Griffith, DC; Gruppen, EG; Guaita, A; Guan, P; Guan, X; Guerci, P; Guerrero, DT; Guo, M; Guo, P; Guo, R; Guo, X; Gupta, J; Guz, G; Hajizadeh, N; Hamada, H; Haman-Wabi, AB; Han, TT; Hannan, N; Hao, S; Harjola, VP; Harmon, M; Hartmann, MSM; Hartwig, JF; Hasani, M; Hawthorne, WJ; Haykal-Coates, N; Hazari, MS; He, DL; He, P; He, SG; Héau, C; Hebbar Kannur, K; Helvaci, O; Heuberger, DM; Hidalgo, F; Hilty, MP; Hirata, K; Hirsch, A; Hoffman, AM; Hoffmann, JF; Holloway, RW; Holmes, RK; Hong, S; Hongisto, M; Hopf, NB; Hörlein, R; Hoshino, N; Hou, Y; Hoven, NF; Hsieh, YY; Hsu, CT; Hu, CW; Hu, JH; Hu, MY; Hu, Y; Hu, Z; Huang, C; Huang, D; Huang, DQ; Huang, L; Huang, Q; Huang, R; Huang, S; Huang, SC; Huang, W; Huang, Y; Huffman, KM; Hung, CH; Hung, CT; Huurman, R; Hwang, SM; Hyun, S; Ibrahim, AM; Iddi-Faical, A; Immordino, P; Isla, MI; Jacquemond, V; Jacques, T; Jankowska, E; Jansen, JA; Jäntti, T; Jaque-Fernandez, F; Jarvis, GA; Jatt, LP; Jeon, JW; Jeong, SH; Jhunjhunwala, R; Ji, F; Jia, X; Jia, Y; Jian-Bo, Z; Jiang, GD; Jiang, L; Jiang, W; Jiang, WD; Jiang, Z; Jiménez-Hoyos, CA; Jin, S; Jobling, MG; John, CM; John, T; Johnson, CB; Jones, KI; Jones, WS; Joseph, OO; Ju, C; Judeinstein, P; Junges, A; Junnarkar, M; Jurkko, R; Kaleka, CC; Kamath, AV; Kang, X; Kantsadi, AL; Kapoor, M; Karim, Z; Kashuba, ADM; Kassa, E; Kasztura, M; Kataja, A; Katoh, T; Kaufman, JS; Kaupp, M; Kehinde, O; Kehrenberg, C; Kemper, N; Kerr, CW; Khan, AU; Khan, MF; Khan, ZUH; Khojasteh, SC; Kilburn, S; Kim, CG; Kim, DU; Kim, DY; Kim, HJ; Kim, J; Kim, OH; Kim, YH; King, C; Klein, A; Klingler, L; Knapp, AK; Ko, TK; Kodavanti, UP; Kolla, V; Kong, L; Kong, RY; Kong, X; Kore, S; Kortz, U; Korucu, B; Kovacs, A; Krahnert, I; Kraus, WE; Kuang, SY; Kuehn-Hajder, JE; Kurz, M; Kuśtrowski, P; Kwak, YD; Kyttaris, VC; Laga, SM; Laguerre, A; Laloo, A; Langaro, MC; Langham, MC; Lao, X; Larocca, MC; Lassus, J; Lattimer, TA; Lazar, S; Le, MH; Leal, DB; Leal, M; Leary, A; Ledermann, JA; Lee, JF; Lee, MV; Lee, NH; Leeds, CM; Leeds, JS; Lefrandt, JD; Leicht, AS; Leonard, M; Lev, S; Levy, K; Li, B; Li, C; Li, CM; Li, DH; Li, H; Li, J; Li, L; Li, LJ; Li, N; Li, P; Li, T; Li, X; Li, XH; Li, XQ; Li, XX; Li, Y; Li, Z; Li, ZY; Liao, YF; Lin, CC; Lin, MH; Lin, Y; Ling, Y; Links, TP; Lira-Romero, E; Liu, C; Liu, D; Liu, H; Liu, J; Liu, L; Liu, LP; Liu, M; Liu, T; Liu, W; Liu, X; Liu, XH; Liu, Y; Liuwantara, D; Ljumanovic, N; Lobo, L; Lokhande, K; Lopes, A; Lopes, RMRM; López-Gutiérrez, JC; López-Muñoz, MJ; López-Santamaría, M; Lorenzo, C; Lorusso, D; Losito, I; Lu, C; Lu, H; Lu, HZ; Lu, SH; Lu, SN; Lu, Y; Lu, ZY; Luboga, F; Luo, JJ; Luo, KL; Luo, Y; Lutomski, CA; Lv, W; M Piedade, MF; Ma, J; Ma, JQ; Ma, JX; Ma, N; Ma, P; Ma, S; Maciel, M; Madureira, M; Maganaris, C; Maginn, EJ; Mahnashi, MH; Maierhofer, M; Majetschak, M; Malla, TR; Maloney, L; Mann, DL; Mansuri, A; Marelli, E; Margulis, CJ; Marrella, A; Martin, BL; Martín-Francés, L; Martínez de Pinillos, M; Martínez-Navarro, EM; Martinez-Quintanilla Jimenez, D; Martínez-Velasco, A; Martínez-Villaseñor, L; Martinón-Torres, M; Martins, BA; Massongo, M; Mathew, AP; Mathews, D; Matsui, J; Matsumoto, KI; Mau, T; Maves, RC; Mayclin, SJ; Mayer, JM; Maynard, ND; Mayr, T; Mboowa, MG; McEvoy, MP; McIntyre, RC; McKay, JA; McPhail, MJW; McVeigh, AL; Mebazaa, A; Medici, V; Medina, DN; Mehmood, T; Mei-Li, C; Melku, M; Meloncelli, S; Mendes, GC; Mendoza-Velásquez, C; Mercadante, R; Mercado, MI; Merenda, MEZ; Meunier, J; Mi, SL; Michels, M; Mijatovic, V; Mikhailov, V; Milheiro, SA; Miller, DC; Ming, F; Mitsuishi, M; Miyashita, T; Mo, J; Mo, S; Modesto-Mata, M; Moeller, S; Monte, A; Monteiro, L; Montomoli, J; Moore, EE; Moore, HB; Moore, PK; Mor, MK; Moratalla-López, N; Moratilla Lapeña, L; Moreira, R; Moreno, MA; Mörk, AC; Morton, M; Mosier, JM; Mou, LH; Mougharbel, AS; Muccillo-Baisch, AL; Muñoz-Serrano, AJ; Mustafa, B; Nair, GM; Nakanishi, I; Nakanjako, D; Naraparaju, K; Nawani, N; Neffati, R; Neil, EC; Neilipovitz, D; Neira-Borrajo, I; Nelson, MT; Nery, PB; Nese, M; Nguyen, F; Nguyen, MH; Niazy, AA; Nicolaï, J; Nogueira, F; Norbäck, D; Novaretti, JV; O'Donnell, T; O'Dowd, A; O'Malley, DM; Oaknin, A; Ogata, K; Ohkubo, K; Ojha, M; Olaleye, MT; Olawande, B; Olomo, EJ; Ong, EWY; Ono, A; Onwumere, J; Ortiz Bibriesca, DM; Ou, X; Oza, AM; Ozturk, K; Özütemiz, C; Palacio-Pastrana, C; Palaparthi, A; Palevsky, PM; Pan, K; Pantanetti, S; Papachristou, DJ; Pariani, A; Parikh, CR; Parissis, J; Paroul, N; Parry, S; Patel, N; Patel, SM; Patel, VC; Pawar, S; Pefura-Yone, EW; Peixoto Andrade, BCO; Pelepenko, LE; Peña-Lora, D; Peng, S; Pérez-Moro, OS; Perez-Ortiz, AC; Perry, LM; Peter, CM; Phillips, NJ; Phillips, P; Pia Tek, J; Piner, LW; Pinto, EA; Pinto, SN; Piyachaturawat, P; Poka-Mayap, V; Polledri, E; Poloni, TE; Ponessa, G; Poole, ST; Post, AK; Potter, TM; Pressly, BB; Prouty, MG; Prudêncio, M; Pulkki, K; Pupier, C; Qian, H; Qian, ZP; Qiu, Y; Qu, G; Rahimi, S; Rahman, AU; Ramadan, H; Ramanna, S; Ramirez, I; Randolph, GJ; Rasheed, A; Rault, J; Raviprakash, V; Reale, E; Redpath, C; Rema, V; Remucal, CK; Remy, D; Ren, T; Ribeiro, LB; Riboli, G; Richards, J; Rieger, V; Rieusset, J; Riva, A; Rivabella Maknis, T; Robbins, JL; Robinson, CV; Roche-Campo, F; Rodriguez, R; Rodríguez-de-Cía, J; Rollenhagen, JE; Rosen, EP; Rub, D; Rubin, N; Rubin, NT; Ruurda, JP; Saad, O; Sabell, T; Saber, SE; Sabet, M; Sadek, MM; Saejio, A; Salinas, RM; Saliu, IO; Sande, D; Sang, D; Sangenito, LS; Santos, ALSD; Sarmiento Caldas, MC; Sassaroli, S; Sassi, V; Sato, J; Sauaia, A; Saunders, K; Saunders, PR; Savarino, SJ; Scambia, G; Scanlon, N; Schetinger, MR; Schinkel, AFL; Schladweiler, MC; Schofield, CJ; Schuepbach, RA; Schulz, J; Schwartz, N; Scorcella, C; Seeley, J; Seemann, F; Seinige, D; Sengoku, T; Seravalli, J; Sgromo, B; Shaheen, MY; Shan, L; Shanmugam, S; Shao, H; Sharma, S; Shaw, KJ; Shen, BQ; Shen, CH; Shen, P; Shen, S; Shen, Y; Shen, Z; Shi, J; Shi-Li, L; Shimoda, K; Shoji, Y; Shun, C; Silva, MA; Silva-Cardoso, J; Simas, NK; Simirgiotis, MJ; Sincock, SA; Singh, MP; Sionis, A; Siu, J; Sivieri, EM; Sjerps, MJ; Skoczen, SL; Slabon, A; Slette, IJ; Smith, MD; Smith, S; Smith, TG; Snapp, KS; Snow, SJ; Soares, MCF; Soberman, D; Solares, MD; Soliman, I; Song, J; Sorooshian, A; Sorrell, TC; Spinar, J; Staudt, A; Steinhart, C; Stern, ST; Stevens, DM; Stiers, KM; Stimming, U; Su, YG; Subbian, V; Suga, H; Sukhija-Cohen, A; Suksamrarn, A; Suksen, K; Sun, J; Sun, M; Sun, P; Sun, W; Sun, XF; Sun, Y; Sundell, J; Susan, LF; Sutjarit, N; Swamy, KV; Swisher, EM; Sykes, C; Takahashi, JA; Talmor, DS; Tan, B; Tan, ZK; Tang, L; Tang, S; Tanner, JJ; Tanwar, M; Tarazi, Z; Tarvasmäki, T; Tay, FR; Teketel, A; Temitayo, GI; Thersleff, T; Thiessen Philbrook, H; Thompson, LC; Thongon, N; Tian, B; Tian, F; Tian, Q; Timothy, AT; Tingle, MD; Titze, IR; Tolppanen, H; Tong, W; Toyoda, H; Tronconi, L; Tseng, CH; Tu, H; Tu, YJ; Tung, SY; Turpault, S; Tuynman, JB; Uemoto, AT; Ugurlu, M; Ullah, S; Underwood, RS; Ungell, AL; Usandizaga-Elio, I; Vakonakis, I; van Boxel, GI; van den Beucken, JJJP; van der Boom, T; van Slegtenhorst, MA; Vanni, JR; Vaquera, A; Vasconcellos, RS; Velayos, M; Vena, R; Ventura, G; Verso, MG; Vincent, RP; Vitale, F; Vitali, S; Vlek, SL; Vleugels, MPH; Volkmann, N; Vukelic, M; Wagner Mackenzie, B; Wairagala, P; Waller, SB; Wan, J; Wan, MT; Wan, Y; Wang, CC; Wang, H; Wang, J; Wang, JF; Wang, K; Wang, L; Wang, M; Wang, S; Wang, WM; Wang, X; Wang, Y; Wang, YD; Wang, YF; Wang, Z; Wang, ZG; Warriner, K; Weberpals, JI; Weerachayaphorn, J; Wehrli, FW; Wei, J; Wei, KL; Weinheimer, CJ; Weisbord, SD; Wen, S; Wendel Garcia, PD; Williams, JW; Williams, R; Winkler, C; Wirman, AP; Wong, S; Woods, CM; Wu, B; Wu, C; Wu, F; Wu, P; Wu, S; Wu, Y; Wu, YN; Wu, ZH; Wurtzel, JGT; Xia, L; Xia, Z; Xia, ZZ; Xiao, H; Xie, C; Xin, ZM; Xing, Y; Xing, Z; Xu, S; Xu, SB; Xu, T; Xu, X; Xu, Y; Xue, L; Xun, J; Yaffe, MB; Yalew, A; Yamamoto, S; Yan, D; Yan, H; Yan, S; Yan, X; Yang, AD; Yang, E; Yang, H; Yang, J; Yang, JL; Yang, K; Yang, M; Yang, P; Yang, Q; Yang, S; Yang, W; Yang, X; Yang, Y; Yao, JC; Yao, WL; Yao, Y; Yaqub, TB; Ye, J; Ye, W; Yen, CW; Yeter, HH; Yin, C; Yip, V; Yong-Yi, J; Yu, HJ; Yu, MF; Yu, S; Yu, W; Yu, WW; Yu, X; Yuan, P; Yuan, Q; Yue, XY; Zaia, AA; Zakhary, SY; Zalwango, F; Zamalloa, A; Zamparo, P; Zampini, IC; Zani, JL; Zeitoun, R; Zeng, N; Zenteno, JC; Zepeda-Palacio, C; Zhai, C; Zhang, B; Zhang, G; Zhang, J; Zhang, K; Zhang, Q; Zhang, R; Zhang, T; Zhang, X; Zhang, Y; Zhang, YY; Zhao, B; Zhao, D; Zhao, G; Zhao, H; Zhao, Q; Zhao, R; Zhao, S; Zhao, T; Zhao, X; Zhao, XA; Zhao, Y; Zhao, Z; Zheng, Z; Zhi-Min, G; Zhou, CL; Zhou, HD; Zhou, J; Zhou, W; Zhou, XQ; Zhou, Z; Zhu, C; Zhu, H; Zhu, L; Zhu, Y; Zitzmann, N; Zou, L; Zou, Y | 1 |
| Aicha, BT; Hana, S; Ines, M; Issam, S; Kawther, BA; Leila, A; Leila, M; Lobna, BA; Mouna, BS; Olfa, S; Rawdha, T; Selma, B; Takoua, BB | 1 |
9 review(s) available for isoxazoles and teriflunomide
| Article | Year |
|---|---|
Leflunomide and malononitrilamides.
Topics: Aniline Compounds; Animals; Arthritis, Rheumatoid; Autoimmune Diseases; Clinical Trials as Topic; Crotonates; Graft Rejection; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Molecular Structure; Nitriles; Organ Transplantation; Toluidines; Transplantation Immunology | 1997 |
The use of leflunomide in the treatment of rheumatoid arthritis: an experimental and clinical review.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Clinical Trials, Phase III as Topic; Crotonates; Drug Therapy, Combination; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Nitriles; Toluidines | 2000 |
Development of a novel drug for transplantation: current results and future perspectives.
Topics: Alkynes; Aniline Compounds; Animals; Autoimmune Diseases; Biological Availability; Crotonates; Drug Design; Graft Rejection; Graft Survival; Graft vs Host Disease; Graft vs Host Reaction; Heart Transplantation; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Nitriles; Skin Transplantation; Toluidines; Transplantation, Homologous | 2001 |
Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis.
Topics: Administration, Oral; Animals; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Crotonates; Disease Models, Animal; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Multiple Sclerosis; Nitriles; Randomized Controlled Trials as Topic; Toluidines | 2013 |
Comparison of two molecular scaffolds, 5-methylisoxazole-3-carboxamide and 5-methylisoxazole-4-carboxamide.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Crotonates; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Mutagenicity Tests; Nitriles; Teratogens; Toluidines; Toxicity Tests, Acute | 2014 |
Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases.
Topics: Animals; Autoimmune Diseases; Crotonates; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Nitriles; Pyrimidines; T-Lymphocytes; Toluidines | 2015 |
[TERIFLUNOMIDE: A NEW ORAL IMMUNOMODULATING AGENT FOR MULTIPLE SCLEROSIS].
Topics: Clinical Trials as Topic; Crotonates; Drug Administration Schedule; Humans; Hydroxybutyrates; Interferon-alpha; Interferon-beta; Isoxazoles; Leflunomide; Multiple Sclerosis; Nitriles; Teratogens; Toluidines | 2015 |
From Leflunomide to Teriflunomide: Drug Development and Immunosuppressive Oral Drugs in the Treatment of Multiple Sclerosis.
Topics: Administration, Oral; Animals; Crotonates; Drug Discovery; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Multiple Sclerosis; Nitriles; Toluidines | 2017 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
8 trial(s) available for isoxazoles and teriflunomide
| Article | Year |
|---|---|
Inhibition of neutrophil migration soon after initiation of treatment with leflunomide or methotrexate in patients with rheumatoid arthritis: findings in a prospective, randomized, double-blind clinical trial in fifteen patients.
Topics: Aged; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; Chemotaxis, Leukocyte; Crotonates; Dose-Response Relationship, Drug; Double-Blind Method; Humans; Hydroxybutyrates; Immunosuppressive Agents; In Vitro Techniques; Interleukin-8; Isoxazoles; Leflunomide; Methotrexate; Middle Aged; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Nitriles; Prospective Studies; Toluidines | 2000 |
Pharmacokinetics of leflunomide in Chinese healthy volunteers.
Topics: Adult; Aniline Compounds; Chromatography, High Pressure Liquid; Crotonates; Female; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Male; Nitriles; Prodrugs; Random Allocation; Toluidines | 2002 |
Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis.
Topics: Adult; Aged; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; Cell Division; Cells, Cultured; Crotonates; Cytokines; Dose-Response Relationship, Drug; Double-Blind Method; Follow-Up Studies; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-gamma; Interleukin-6; Isoxazoles; Leflunomide; Methotrexate; Middle Aged; Nitriles; Toluidines | 2004 |
Safety and efficacy of leflunomide in primary Sjögren's syndrome: a phase II pilot study.
Topics: Adult; Aniline Compounds; Crotonates; Diarrhea; Facial Dermatoses; Fatigue; Female; Humans; Hydroxybutyrates; Immunoglobulin G; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus Erythematosus, Systemic; Middle Aged; Nitriles; Pilot Projects; Sjogren's Syndrome; Statistics, Nonparametric; Toluidines; Vasculitis | 2007 |
Pharmacokinetics and pharmacodynamics of A77 1726 and leflunomide in domestic cats.
Topics: Administration, Oral; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Cats; Crotonates; Half-Life; Hydroxybutyrates; Injections, Intravenous; Isoxazoles; Leflunomide; Male; Nitriles; Toluidines | 2012 |
Comparative bioequivalence study of leflunomide tablets in Indian healthy volunteers.
Topics: Adult; Antirheumatic Agents; Area Under Curve; Biological Availability; Chromatography, High Pressure Liquid; Confidence Intervals; Cross-Over Studies; Crotonates; Half-Life; Humans; Hydroxybutyrates; India; Indicators and Reagents; Isoxazoles; Leflunomide; Male; Nitriles; Spectrophotometry, Ultraviolet; Tablets; Therapeutic Equivalency; Toluidines; Young Adult | 2012 |
Pharmacokinetics and bioequivalence evaluation of leflunomide tablets in Korean healthy volunteers.
Topics: Adult; Analysis of Variance; Antirheumatic Agents; Area Under Curve; Cross-Over Studies; Crotonates; Dose-Response Relationship, Drug; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Middle Aged; Nitriles; Republic of Korea; Therapeutic Equivalency; Toluidines; Young Adult | 2013 |
Topics: 3T3-L1 Cells; A Kinase Anchor Proteins; Acetates; Achilles Tendon; Acute Kidney Injury; Acute Pain; Acyclic Monoterpenes; Adenine Nucleotides; Adhesins, Escherichia coli; Adipocytes; Adipocytes, Brown; Adipogenesis; Administration, Inhalation; Administration, Oral; Adrenal Cortex Hormones; Adsorption; Adult; Aeromonas hydrophila; Africa; Aged; Aged, 80 and over; Agrobacterium tumefaciens; Air; Air Pollutants; Air Pollution; Air Pollution, Indoor; Algorithms; Alkaloids; Alkynes; Allosteric Regulation; Amines; Amino Acid Sequence; Amino Acids; Amino Acids, Branched-Chain; Aminoisobutyric Acids; Aminopyridines; Amyotrophic Lateral Sclerosis; Anaerobic Threshold; Angiography; Angiotensin II Type 1 Receptor Blockers; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animal Distribution; Animal Feed; Animal Nutritional Physiological Phenomena; Animals; Ankle Joint; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Inflammatory Agents; Antibodies, Bacterial; Antifungal Agents; Antimalarials; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antioxidants; Antiretroviral Therapy, Highly Active; Antiviral Agents; Aotidae; Apelin; Apoptosis; Arabidopsis Proteins; Argentina; Arginine; Artemisinins; Arthritis, Experimental; Arthritis, Rheumatoid; Arthroscopy; Aspergillus; Aspergillus niger; Asteraceae; Asthma; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; Auditory Cortex; Autoantibodies; Autophagy; Bacteria; Bacterial Infections; Bacterial Proteins; Bacterial Typing Techniques; Base Composition; Base Sequence; Basketball; Beclin-1; Benzhydryl Compounds; Benzimidazoles; Benzo(a)pyrene; Benzofurans; Benzoxazines; Bereavement; beta Catenin; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Betacoronavirus; Betaine; Binding Sites; Biofilms; Biological Assay; Biological Availability; Biological Evolution; Biomarkers; Biomechanical Phenomena; Biopolymers; Biopsy; Bismuth; Blood Glucose; Blood Platelets; Blood Pressure; Body Composition; Body Weight; Bone Marrow; Bone Marrow Cells; Bone Regeneration; Boron; Botrytis; Brain Ischemia; Brain Neoplasms; Brain-Derived Neurotrophic Factor; Brazil; Breast Neoplasms; Breath Tests; Bronchoalveolar Lavage Fluid; Burkholderia; C-Reactive Protein; Caenorhabditis elegans; Caenorhabditis elegans Proteins; Calcification, Physiologic; Calcium; Calcium Signaling; Calorimetry, Differential Scanning; Cameroon; Camptothecin; Candida; Candida albicans; Capillaries; Carbapenem-Resistant Enterobacteriaceae; Carbapenems; Carbohydrate Conformation; Carbon; Carbon Dioxide; Carbon Isotopes; Carcinoma, Ovarian Epithelial; Cardiac Output; Cardiomyopathy, Hypertrophic; Cardiotonic Agents; Cardiovascular Diseases; Caregivers; Carps; Case-Control Studies; Catalase; Catalysis; Cats; CD4 Lymphocyte Count; Cell Culture Techniques; Cell Differentiation; Cell Line, Tumor; Cell Membrane; Cell Movement; Cell Proliferation; Cell Survival; Cells, Cultured; Cellulose; Centrosome; Ceratopogonidae; Chickens; Child; China; Cholera Toxin; Choline; Cholinesterases; Chromatography, High Pressure Liquid; Chromatography, Liquid; Chromatography, Micellar Electrokinetic Capillary; Chromatography, Reverse-Phase; Chronic Disease; Cinnamates; Cities; Citrates; Climate Change; Clinical Trials, Phase III as Topic; Coal; Coal Mining; Cohort Studies; Coinfection; Colchicine; Colony Count, Microbial; Colorectal Neoplasms; Coloring Agents; Common Cold; Complement Factor H; Computational Biology; Computer Simulation; Continuous Positive Airway Pressure; Contrast Media; Coordination Complexes; Coronary Artery Bypass; Coronavirus 3C Proteases; Coronavirus Infections; Coronavirus Protease Inhibitors; Corynebacterium glutamicum; Cosmetics; COVID-19; Creatinine; Cross-Sectional Studies; Crotonates; Crystallography, X-Ray; Cues; Culicidae; Culture Media; Curcuma; Cyclopentanes; Cyclopropanes; Cymbopogon; Cystine; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2C19 Inhibitors; Cytokines; Databases, Genetic; Death; Dendritic Cells; Density Functional Theory; Depsides; Diabetes Mellitus, Type 2; Diamond; Diarylheptanoids; Dibenzofurans; Dibenzofurans, Polychlorinated; Diclofenac; Diet; Dietary Carbohydrates; Dietary Supplements; Diffusion Magnetic Resonance Imaging; Dioxins; Diphenylamine; Disease Outbreaks; Disease Susceptibility; Disulfides; Dithiothreitol; Dizocilpine Maleate; DNA Methylation; DNA-Binding Proteins; DNA, Bacterial; Dogs; Dose-Response Relationship, Drug; Double-Blind Method; Doublecortin Protein; Drosophila melanogaster; Droughts; Drug Carriers; Drug Combinations; Drug Delivery Systems; Drug Liberation; Drug Resistance; Drug Resistance, Bacterial; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Dust; Dynactin Complex; Dysferlin; Echo-Planar Imaging; Echocardiography; Edaravone; Egypt; Elasticity; Electrodes; Electrolytes; Emodin; Emtricitabine; Endometriosis; Endothelium, Vascular; Endotoxins; Energy Metabolism; Energy Transfer; Enterobacteriaceae; Enterococcus faecalis; Enterotoxigenic Escherichia coli; Environmental Monitoring; Enzyme Inhibitors; Epidemiologic Factors; Epigenesis, Genetic; Erythrocytes; Escherichia coli; Escherichia coli Infections; Escherichia coli Vaccines; Esophageal Neoplasms; Esophagectomy; Esophagogastric Junction; Esterases; Esterification; Ethanol; Ethiopia; Ethnicity; Eucalyptus; Evidence-Based Practice; Exercise; Exercise Tolerance; Extracorporeal Membrane Oxygenation; Family; Fatty Acids; Feedback; Female; Ferric Compounds; Fibrin Fibrinogen Degradation Products; Filtration; Fish Diseases; Flavonoids; Flavonols; Fluorodeoxyglucose F18; Follow-Up Studies; Food Microbiology; Food Preservation; Forests; Fossils; Free Radical Scavengers; Freund's Adjuvant; Fruit; Fungi; Gallium; Gender Identity; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Gene Expression Regulation, Plant; Gene Knockdown Techniques; Genes, Bacterial; Genes, Plant; Genetic Predisposition to Disease; Genitalia; Genotype; Glomerulonephritis, IGA; Glottis; Glucocorticoids; Glucose; Glucuronides; Glutathione Transferase; Glycogen Synthase Kinase 3 beta; Gram-Negative Bacterial Infections; Gram-Positive Bacterial Infections; Grassland; Guinea Pigs; Half-Life; Head Kidney; Heart Atria; Heart Rate; Heart Septum; HEK293 Cells; Hematopoietic Stem Cells; Hemodynamics; Hep G2 Cells; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Hepatocytes; Hesperidin; High-Frequency Ventilation; High-Temperature Requirement A Serine Peptidase 1; Hippocampus; Hirudins; History, 20th Century; History, 21st Century; HIV Infections; Homeostasis; Hominidae; Housing, Animal; Humans; Hydrocarbons, Brominated; Hydrogen Bonding; Hydrogen Peroxide; Hydrogen-Ion Concentration; Hydroxybutyrates; Hydroxyl Radical; Hypertension; Hypothyroidism; Image Interpretation, Computer-Assisted; Immunoconjugates; Immunogenic Cell Death; Indoles; Infant, Newborn; Infant, Premature; Infarction, Middle Cerebral Artery; Inflammation; Inflammation Mediators; Infrared Rays; Inhibitory Concentration 50; Injections, Intravenous; Interferon-gamma; Interleukin-23; Interleukin-4; Interleukin-6; Intermediate Filaments; Intermittent Claudication; Intestine, Small; Iridoid Glucosides; Iridoids; Iron; Isomerism; Isotope Labeling; Isoxazoles; Itraconazole; Kelch-Like ECH-Associated Protein 1; Ketoprofen; Kidney Failure, Chronic; Kinetics; Klebsiella pneumoniae; Lactams, Macrocyclic; Lactobacillus; Lactulose; Lakes; Lamivudine; Laparoscopy; Laparotomy; Laryngoscopy; Leucine; Limit of Detection; Linear Models; Lipid A; Lipopolysaccharides; Listeria monocytogenes; Liver; Liver Cirrhosis; Logistic Models; Longitudinal Studies; Losartan; Low Back Pain; Lung; Lupinus; Lupus Erythematosus, Systemic; Machine Learning; Macular Degeneration; Madin Darby Canine Kidney Cells; Magnetic Phenomena; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Magnetics; Malaria, Falciparum; Male; Mannans; MAP Kinase Signaling System; Mass Spectrometry; Melatonin; Membrane Glycoproteins; Membrane Proteins; Meniscectomy; Menisci, Tibial; Mephenytoin; Mesenchymal Stem Cells; Metal Nanoparticles; Metal-Organic Frameworks; Methionine; Mice; Mice, Inbred C57BL; Mice, Knockout; Mice, Nude; Mice, Obese; Mice, Transgenic; Microbial Sensitivity Tests; Microcirculation; MicroRNAs; Microscopy, Video; Microtubules; Microvascular Density; Microwaves; Middle Aged; Minimally Invasive Surgical Procedures; Models, Animal; Models, Biological; Models, Molecular; Models, Theoretical; Molecular Docking Simulation; Molecular Structure; Molecular Weight; Morus; Mouth Floor; Multicenter Studies as Topic; Multiple Sclerosis; Multiple Sclerosis, Relapsing-Remitting; Muscle, Skeletal; Myocardial Ischemia; Myocardium; NAD; NADP; Nanocomposites; Nanoparticles; Naphthols; Nasal Lavage Fluid; Nasal Mucosa; Neisseria meningitidis; Neoadjuvant Therapy; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasms, Experimental; Neural Stem Cells; Neuroblastoma; Neurofilament Proteins; Neurogenesis; Neurons; New York; NF-E2-Related Factor 2; NF-kappa B; Nicotine; Nitriles; Nitrogen; Nitrogen Fixation; North America; Observer Variation; Occupational Exposure; Ochrobactrum; Oils, Volatile; Olea; Oligosaccharides; Omeprazole; Open Field Test; Optimism; Oregon; Oryzias; Osmolar Concentration; Osteoarthritis; Osteoblasts; Osteogenesis; Ovarian Neoplasms; Ovariectomy; Oxadiazoles; Oxidation-Reduction; Oxidative Stress; Oxygen; Ozone; p38 Mitogen-Activated Protein Kinases; Pakistan; Pandemics; Particle Size; Particulate Matter; Patient-Centered Care; Pelargonium; Peptides; Perception; Peripheral Arterial Disease; Peroxides; Pets; Pharmaceutical Preparations; Pharmacogenetics; Phenobarbital; Phenols; Phenotype; Phosphates; Phosphatidylethanolamines; Phosphines; Phospholipids; Phosphorus; Phosphorylation; Photoacoustic Techniques; Photochemotherapy; Photosensitizing Agents; Phylogeny; Phytoestrogens; Pilot Projects; Plant Components, Aerial; Plant Extracts; Plant Immunity; Plant Leaves; Plant Oils; Plants, Medicinal; Plasmodium berghei; Plasmodium falciparum; Platelet Activation; Platelet Function Tests; Pneumonia, Viral; Poaceae; Pogostemon; Poloxamer; Poly I; Poly(ADP-ribose) Polymerase Inhibitors; Polychlorinated Biphenyls; Polychlorinated Dibenzodioxins; Polycyclic Compounds; Polyethylene Glycols; Polylysine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Population Dynamics; Portasystemic Shunt, Transjugular Intrahepatic; Positron Emission Tomography Computed Tomography; Postoperative Complications; Postprandial Period; Potassium Cyanide; Predictive Value of Tests; Prefrontal Cortex; Pregnancy; Prepulse Inhibition; Prevalence; Procalcitonin; Prodrugs; Prognosis; Progression-Free Survival; Proline; Proof of Concept Study; Prospective Studies; Protein Binding; Protein Conformation; Protein Domains; Protein Folding; Protein Multimerization; Protein Sorting Signals; Protein Structure, Secondary; Proton Pump Inhibitors; Protozoan Proteins; Psychometrics; Pulse Wave Analysis; Pyridines; Pyrrolidines; Quality of Life; Quantum Dots; Quinoxalines; Quorum Sensing; Radiopharmaceuticals; Rain; Random Allocation; Randomized Controlled Trials as Topic; Rats; Rats, Sprague-Dawley; Rats, Wistar; RAW 264.7 Cells; Reactive Oxygen Species; Receptor, Angiotensin, Type 1; Receptor, PAR-1; Receptors, CXCR4; Receptors, Estrogen; Receptors, Glucocorticoid; Receptors, Interleukin-1; Receptors, Interleukin-17; Receptors, Notch; Recombinant Fusion Proteins; Recombinant Proteins; Reducing Agents; Reflex, Startle; Regional Blood Flow; Regression Analysis; Reperfusion Injury; Reproducibility of Results; Republic of Korea; Respiratory Tract Diseases; Retrospective Studies; Reverse Transcriptase Inhibitors; Rhinitis, Allergic; Risk Assessment; Risk Factors; Rituximab; RNA, Messenger; RNA, Ribosomal, 16S; ROC Curve; Rosmarinic Acid; Running; Ruthenium; Rutin; Sarcolemma; Sarcoma; Sarcopenia; Sarcoplasmic Reticulum; SARS-CoV-2; Scavenger Receptors, Class A; Schools; Seasons; Seeds; Sequence Analysis, DNA; Severity of Illness Index; Sex Factors; Shock, Cardiogenic; Short Chain Dehydrogenase-Reductases; Signal Transduction; Silver; Singlet Oxygen; Sinusitis; Skin; Skin Absorption; Small Molecule Libraries; Smoke; Socioeconomic Factors; Soil; Soil Microbiology; Solid Phase Extraction; Solubility; Solvents; Spain; Spectrometry, Mass, Electrospray Ionization; Spectroscopy, Fourier Transform Infrared; Speech; Speech Perception; Spindle Poles; Spleen; Sporothrix; Staphylococcal Infections; Staphylococcus aureus; Stereoisomerism; Stomach Neoplasms; Stress, Physiological; Stroke Volume; Structure-Activity Relationship; Substrate Specificity; Sulfonamides; Surface Properties; Surface-Active Agents; Surveys and Questionnaires; Survival Rate; T-Lymphocytes, Cytotoxic; Tandem Mass Spectrometry; Temperature; Tenofovir; Terpenes; Tetracycline; Tetrapleura; Textiles; Thermodynamics; Thiobarbituric Acid Reactive Substances; Thrombin; Thyroid Hormones; Thyroid Neoplasms; Tibial Meniscus Injuries; Time Factors; Tissue Distribution; Titanium; Toluidines; Tomography, X-Ray Computed; Tooth; Tramadol; Transcription Factor AP-1; Transcription, Genetic; Transfection; Transgender Persons; Translations; Treatment Outcome; Triglycerides; Ubiquinone; Ubiquitin-Specific Proteases; United Kingdom; United States; Up-Regulation; Vascular Stiffness; Veins; Ventricular Remodeling; Viral Load; Virulence Factors; Virus Replication; Vitis; Voice; Voice Quality; Wastewater; Water; Water Pollutants, Chemical; Water-Electrolyte Balance; Weather; Wildfires; Wnt Signaling Pathway; Wound Healing; X-Ray Diffraction; Xenograft Model Antitumor Assays; Young Adult; Zoogloea | 2022 |
106 other study(ies) available for isoxazoles and teriflunomide
| Article | Year |
|---|---|
Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.
Topics: Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cell Line; Crotonates; Dihydroorotate Dehydrogenase; Dose-Response Relationship, Drug; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Kinetics; Leflunomide; Lymphocytes; Mitochondria; Nitriles; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Toluidines; Ubiquinone; Uridine Monophosphate | 1995 |
Measurement of the active leflunomide metabolite (A77 1726) by reverse-phase high-performance liquid chromatography.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Crotonates; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Nitriles; Rabbits; Toluidines | 1995 |
Leflunomide (HWA 486) and its analog suppress T- and B-cell proliferation in vitro, acute rejection, ongoing rejection, and antidonor antibody synthesis in mouse, rat, and cynomolgus monkey transplant recipients as well as arterial intimal thickening afte
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arteries; B-Lymphocytes; Catheterization; Crotonates; Cyclosporine; Graft Rejection; Graft Survival; Heart Transplantation; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocyte Activation; Macaca fascicularis; Male; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Nitriles; Rats; Rats, Inbred BN; Rats, Inbred Lew; T-Lymphocytes; Toluidines; Transplantation, Homologous; Tunica Intima | 1995 |
Effect of leflunomide on constitutive and inducible pathways of cellular eicosanoid generation.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Bone Marrow; Bone Marrow Cells; Crotonates; Dinoprostone; Humans; Hydroxybutyrates; Hydroxyeicosatetraenoic Acids; Indomethacin; Isoxazoles; Leflunomide; Leukotriene B4; Lipopolysaccharides; Mice; Neutrophils; Nitriles; Prostaglandin-Endoperoxide Synthases; Rabbits; Sheep; Toluidines | 1994 |
Leflunomide inhibits cytokine-induced DNA synthesis of rabbit synovial cells in culture.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Division; Cells, Cultured; Crotonates; Cytokines; DNA; Hydroxybutyrates; Isoxazoles; Leflunomide; Nitriles; Rabbits; Synovial Membrane; Toluidines | 1994 |
[Leflunomide inhibits PAF induced DNA synthesis in rabbit synovial cells and PAF production from rat peritoneal macrophages].
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Crotonates; DNA; Hydroxybutyrates; Isoxazoles; Leflunomide; Macrophages, Peritoneal; Nitriles; Platelet Activating Factor; Rabbits; Rats; Synovial Membrane; Toluidines | 1994 |
Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Squamous Cell; Cell Line; Cells, Cultured; Crotonates; ErbB Receptors; Fibroblasts; Humans; Hydroxybutyrates; Isoxazoles; KB Cells; Leflunomide; Male; Nitriles; Phosphorylation; Skin; Toluidines; Tumor Cells, Cultured | 1993 |
Effects of leflunomide (HWA 486) on expression of lymphocyte activation markers.
Topics: Adult; Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Crotonates; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Lymphocyte Activation; Nitriles; Phytohemagglutinins; Receptors, Interleukin-2; Receptors, Transferrin; Toluidines | 1993 |
The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase.
Topics: Aniline Compounds; Crotonates; Dihydroorotate Dehydrogenase; Enzyme Inhibitors; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Kinetics; Leflunomide; Nitriles; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Recombinant Proteins; Toluidines | 1996 |
Blood distribution and single-dose pharmacokinetics of leflunomide.
Topics: Administration, Oral; Aniline Compounds; Animals; Biological Availability; Chromatography, High Pressure Liquid; Computer Simulation; Crotonates; Half-Life; Hydroxybutyrates; Immunosuppressive Agents; Injections, Intravenous; Isoxazoles; Leflunomide; Lipoproteins; Nitriles; Rabbits; Toluidines; Ultracentrifugation | 1995 |
Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
Topics: Aniline Compounds; Animals; Cell Division; Cell Line; Crotonates; Fibroblast Growth Factor 2; Growth Inhibitors; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Mice; Muscle, Smooth; Nitriles; Toluidines; Uridine | 1995 |
Inhibition of smooth muscle cell proliferation in vitro by leflunomide, a new immunosuppressant, is antagonized by uridine.
Topics: Aniline Compounds; Animals; Cell Division; Cell Line, Transformed; Crotonates; Graft Rejection; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Mice; Muscle, Smooth; Nitriles; Toluidines; Uridine | 1995 |
Single- and multiple-dose pharmacokinetics and pharmacodynamics of leflunomide's active metabolite A77 1726 in normal Lewis rats.
Topics: Administration, Oral; Aniline Compounds; Animals; Crotonates; DNA; Dose-Response Relationship, Drug; Drug Administration Schedule; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocyte Activation; Male; Metabolic Clearance Rate; Nitriles; Rats; Rats, Inbred Lew; Thymidine; Time Factors; Toluidines | 1996 |
In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice.
Topics: Aniline Compounds; Animals; Autoimmune Diseases; Crotonates; Dihydroorotate Dehydrogenase; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymph Nodes; Lymphoproliferative Disorders; Mice; Mice, Mutant Strains; Nitriles; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Pyrimidine Nucleotides; Toluidines; Uridine | 1997 |
A new rational hypothesis for the pharmacophore of the active metabolite of leflunomide, a potent immunosuppressive drug.
Topics: Aniline Compounds; Animals; Crotonates; Female; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocyte Culture Test, Mixed; Mice; Mice, Inbred BALB C; Nitriles; Prodrugs; Structure-Activity Relationship; Toluidines | 1997 |
Malononitrilamides 715 and 279 prolong rat cardiac allograft survival, reverse ongoing rejection, inhibit allospecific antibody production and interact positively with cyclosporin.
Topics: Alkynes; Aniline Compounds; Animals; Antibody Formation; Crotonates; Cyclosporine; Drug Interactions; Graft Rejection; Graft Survival; Heart Transplantation; Humans; Hydroxybutyrates; Immunoglobulin Allotypes; Immunosuppressive Agents; Isoxazoles; Nitriles; Rats; Rats, Inbred Strains; Toluidines; Transplantation, Homologous | 1998 |
Prevention of experimental autoimmune diabetes in mice by treatment with leflunomide.
Topics: Aniline Compounds; Animals; Crotonates; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Fibrosis; Hydroxybutyrates; Immunosuppressive Agents; Islets of Langerhans; Isoxazoles; Leflunomide; Male; Mice; Mice, Inbred CBA; Nitriles; Toluidines | 1998 |
Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy.
Topics: Aniline Compounds; Animals; Crotonates; Dog Diseases; Dogs; Female; Hydroxybutyrates; Immune System Diseases; Immunosuppressive Agents; Inflammation; Isoxazoles; Leflunomide; Male; Nitriles; Syndrome; Toluidines | 1998 |
Oral administration of leflunomide (HWA486) results in prominent suppression of immunoglobulin E formation in a rat type 1 allergy model.
Topics: Administration, Oral; Aniline Compounds; Animals; Antibody Specificity; Crotonates; Disease Models, Animal; Drug Administration Schedule; Female; Hydroxybutyrates; Hypersensitivity, Immediate; Immunoglobulin E; Immunoglobulin G; Immunoglobulin M; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocyte Activation; Nitriles; Ovalbumin; Rats; Rats, Inbred BN; Toluidines; Uridine | 1999 |
Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.
Topics: Aniline Compounds; Biological Transport; Cell Nucleus; Ceramides; Chloramphenicol O-Acetyltransferase; Crotonates; Dithiothreitol; DNA-Binding Proteins; Enzyme Activation; Gene Expression Regulation; Genes, MDR; Genes, Reporter; Host Cell Factor C1; Humans; Hydrogen Peroxide; Hydroxybutyrates; I-kappa B Proteins; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lipopolysaccharides; Lymphocyte Specific Protein Tyrosine Kinase p56(lck); Mitogen-Activated Protein Kinase Kinases; NF-kappa B; NF-kappa B p50 Subunit; NF-KappaB Inhibitor alpha; Nitriles; Octamer Transcription Factor-1; Okadaic Acid; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Tetradecanoylphorbol Acetate; Toluidines; Transcription Factor AP-1; Transcription Factor RelA; Transcription Factors; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1999 |
Potentiation of immunosuppressive efficacy by combining the novel leflunomide analog, HMR 279, with microemulsion cyclosporine in a rat lung transplant model.
Topics: Amides; Aniline Compounds; Animals; Biotransformation; Body Weight; Chromatography, High Pressure Liquid; Crotonates; Cyclosporine; Drug Therapy, Combination; Emulsions; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lung Transplantation; Male; Nitriles; Rats; Rats, Inbred BN; Rats, Inbred Lew; Structure-Activity Relationship; Toluidines | 1999 |
Differential modulation of pro- and anti-inflammatory cytokine receptors by N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxy-crotonic acid amide (A77 1726), the physiologically active metabolite of the novel immunomodulator leflunomide.
Topics: Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Cell Division; Cell Line, Transformed; Cell Survival; Crotonates; Gene Expression Regulation; Genes, p53; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Nitriles; Receptors, Interleukin; Receptors, Interleukin-10; Receptors, Interleukin-8A; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Toluidines; Transcription, Genetic; Tumor Suppressor Protein p53 | 1998 |
National Meeting of the American College of Rheumatology. November 8-12, 1998, San Diego, California.
Topics: Aniline Compounds; Anti-Inflammatory Agents; Antibodies, Monoclonal; Arthritis, Rheumatoid; Crotonates; Etanercept; Humans; Hydroxybutyrates; Immunoglobulin G; Immunoglobulin gamma-Chains; Immunoglobulin Heavy Chains; Infliximab; Isoxazoles; Leflunomide; Nitriles; Receptors, Tumor Necrosis Factor; Recombinant Fusion Proteins; Toluidines; Tumor Necrosis Factor-alpha; United States | 1999 |
Flow cytometric analysis of the molecular mechanisms of immunosuppressive action of the active metabolite of leflunomide and its malononitrilamide analogues in a novel whole blood assay.
Topics: Acrylamides; Alkynes; Aniline Compounds; Animals; Biphenyl Compounds; Caproates; Crotonates; Cyclosporine; Dose-Response Relationship, Drug; Flow Cytometry; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocyte Activation; Lymphocytes; Male; Nitriles; Rats; Rats, Inbred Lew; Receptors, Interleukin-2; Receptors, OX40; Receptors, Tumor Necrosis Factor; Toluidines; Tumor Necrosis Factor Receptor Superfamily, Member 7 | 1999 |
In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression.
Topics: Aniline Compounds; Animals; Cricetinae; Crotonates; Graft Rejection; Heart Transplantation; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Liver; Lymph Nodes; Mesocricetus; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Nitriles; Pyrimidine Nucleotides; Rats; Rats, Inbred Lew; Spleen; Toluidines; Transplantation, Heterologous; Transplantation, Homologous; Uridine | 1999 |
A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner.
Topics: 6-Ketoprostaglandin F1 alpha; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonic Acid; Blotting, Western; Cell Survival; Crotonates; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dinoprostone; Enzyme Induction; Enzyme Inhibitors; Humans; Hydroxybutyrates; In Vitro Techniques; Isoenzymes; Isoxazoles; Leflunomide; Macrophages; Male; Membrane Proteins; Mice; Nitric Oxide; Nitric Oxide Synthase; Nitriles; Prostaglandin-Endoperoxide Synthases; Rats; Rats, Wistar; Substrate Specificity; Toluidines | 1999 |
In vitro and in vivo antitumor activity of a novel immunomodulatory drug, leflunomide: mechanisms of action.
Topics: 3T3 Cells; Adjuvants, Immunologic; Aniline Compounds; Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Crotonates; Drug Screening Assays, Antitumor; ErbB Receptors; Female; Glioma; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Nitriles; Phosphorylation; Pyrimidine Nucleotides; Receptors, Growth Factor; Receptors, Platelet-Derived Growth Factor; Toluidines; Tumor Cells, Cultured; Tyrosine | 1999 |
Identification and characterization of potential new therapeutic targets in inflammatory and autoimmune diseases.
Topics: Amino Acid Sequence; Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrier Proteins; Cell Line; Chromatography, Affinity; Crotonates; HeLa Cells; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Kinetics; Leflunomide; Mice; Molecular Sequence Data; Nitriles; Protein Binding; Toluidines | 1999 |
In vivo lymphoproliferation in the popliteal lymph node (PLN) assay can be inhibited by leflunomide's active metabolite A77 1726.
Topics: Aniline Compounds; Animals; Crotonates; Dose-Response Relationship, Drug; Graft vs Host Reaction; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymph Nodes; Lymphocyte Activation; Nitriles; Rats; Rats, Inbred BN; Rats, Inbred Lew; Toluidines | 1999 |
Disease-modifying activity of malononitrilamides, derivatives of leflunomide's active metabolite, on models of rheumatoid arthritis.
Topics: Acrylamides; Alkynes; Aniline Compounds; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Caproates; Crotonates; Dose-Response Relationship, Drug; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Nitriles; Rats; Rats, Inbred Lew; Toluidines | 1999 |
Cell cycle regulation and inhibition of de novo pyrimidine biosynthesis by leflunomide.
Topics: Aniline Compounds; Cell Cycle; Crotonates; Dihydroorotate Dehydrogenase; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Jurkat Cells; Leflunomide; Nitriles; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Pyrimidines; Toluidines | 1999 |
The antiproliferative effect of malononitrilamides (MNAs) on vascular smooth muscle cells is antagonized by exogenous uridine.
Topics: Acrylamides; Alkynes; Aniline Compounds; Animals; Caproates; Cell Division; Crotonates; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Muscle, Smooth, Vascular; Nitriles; Platelet-Derived Growth Factor; Rats; Toluidines; Uridine | 1999 |
Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.
Topics: Amino Acid Sequence; Aniline Compounds; Animals; Binding Sites; Biphenyl Compounds; Catalytic Domain; Crotonates; Crystallography, X-Ray; Dihydroorotate Dehydrogenase; Growth Inhibitors; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Macromolecular Substances; Models, Molecular; Molecular Sequence Data; Nitriles; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Protein Conformation; Protein Structure, Tertiary; Sequence Homology, Amino Acid; Static Electricity; Toluidines | 2000 |
Cell-specific inhibition of inducible nitric oxide synthase activation by leflunomide.
Topics: Adjuvants, Immunologic; Aniline Compounds; Animals; Catalysis; Cells, Cultured; Crotonates; DNA-Binding Proteins; Enzyme Inhibitors; Female; Fibroblasts; Flavonoids; Hydroxybutyrates; Interferon Regulatory Factor-1; Interferon-gamma; Isoxazoles; Leflunomide; Mice; Mice, Inbred CBA; Mitogen-Activated Protein Kinases; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Nitriles; Phosphoproteins; Rats; RNA, Messenger; Toluidines; Tumor Cells, Cultured | 2000 |
Multiple inhibitor analysis of the brequinar and leflunomide binding sites on human dihydroorotate dehydrogenase.
Topics: Aniline Compounds; Antimycin A; Binding, Competitive; Biphenyl Compounds; Calorimetry; Crotonates; Dihydroorotate Dehydrogenase; Enzyme Inhibitors; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Nitriles; Orotic Acid; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Substrate Specificity; Sulfonium Compounds; Titrimetry; Toluidines; Tryptophan | 2001 |
Modulation of human peripheral blood mononuclear cell activation by the combination of leflunomide and pentoxifylline.
Topics: Aniline Compounds; Apoptosis; Cells, Cultured; Crotonates; Drug Interactions; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocyte Activation; Lymphocytes; Nitriles; Pentoxifylline; Phosphodiesterase Inhibitors; Toluidines | 2001 |
Inhibition of cyclosporin-resistant B-cell antigen responses by pyrazoles: a tool for the identification of novel molecular mechanisms of B-cell activation.
Topics: Aniline Compounds; Animals; Antigens, Heterophile; B-Lymphocytes; Biphenyl Compounds; Cell Division; Crotonates; Cyclosporine; Drug Resistance; Graft Rejection; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocyte Activation; Lymphoma, B-Cell; Mycophenolic Acid; Nitriles; Primates; Pyrazoles; Swine; T-Lymphocytes; Toluidines; Transplantation, Heterologous; Tumor Cells, Cultured | 2001 |
Leflunomide induces apoptosis of thymocytes and T-cell hybridoma: differences in sensitivity and signaling pathways.
Topics: Aniline Compounds; Animals; Antibodies, Monoclonal; Apoptosis; Crotonates; Cysteine Proteinase Inhibitors; Dexamethasone; Glucocorticoids; Hybridomas; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Nitriles; Rats; Receptors, Antigen, T-Cell, alpha-beta; T-Lymphocytes; Tetradecanoylphorbol Acetate; Toluidines | 2001 |
Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors.
Topics: Aniline Compounds; Anti-HIV Agents; Anti-Inflammatory Agents, Non-Steroidal; Crotonates; HIV; HIV Core Protein p24; HIV Seronegativity; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lymphocytes; Nitriles; Reverse Transcriptase Inhibitors; Toluidines; Virus Replication; Zidovudine | 2001 |
A77 1726 induces differentiation of human myeloid leukemia K562 cells by depletion of intracellular CTP pools.
Topics: Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Aspartate Carbamoyltransferase; Carbamoyl-Phosphate Synthase (Glutamine-Hydrolyzing); Cell Cycle Proteins; Cell Differentiation; Cell Division; Crotonates; Cytidine; Cytidine Triphosphate; Dihydroorotase; Drug Interactions; Gene Expression; Glycophorins; Humans; Hydroxybutyrates; Isoxazoles; K562 Cells; Leflunomide; Multienzyme Complexes; Nitriles; Pyrimidines; S Phase; Toluidines; Uridine; Uridine Triphosphate | 2002 |
Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms.
Topics: Aniline Compounds; Animals; Cell Line; Cell Survival; Cells, Cultured; Coloring Agents; Crotonates; Cyclic AMP; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Fibroblasts; Guanidines; Humans; Hydroxybutyrates; Immunosuppressive Agents; Interferon-gamma; Interleukin-6; Isoxazoles; Leflunomide; Macrophages; Mice; Mycophenolic Acid; Nitric Oxide Synthase; Nitriles; omega-N-Methylarginine; Phosphodiesterase Inhibitors; Rolipram; Tetrazolium Salts; Thiazoles; Time Factors; Toluidines | 2002 |
Synthesis of beta-hydroxy-propenamide derivatives and the inhibition of human dihydroorotate dehydrogenase.
Topics: Aniline Compounds; Crotonates; Dihydroorotate Dehydrogenase; Enzyme Inhibitors; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; Toluidines | 2003 |
Simultaneous determination of leflunomide and its active metabolite, A77 1726, in human plasma by high-performance liquid chromatography.
Topics: Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; Chromatography, High Pressure Liquid; Crotonates; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Nitriles; Reference Standards; Reproducibility of Results; Spectrophotometry, Ultraviolet; Toluidines | 2003 |
In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Crotonates; Cytochrome P-450 Enzyme System; Desiccation; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Male; Microsomes, Liver; Nitriles; Oximes; Rats; Rats, Sprague-Dawley; Toluidines | 2003 |
The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chondrocytes.
Topics: Adult; Aniline Compounds; Cells, Cultured; Child; Chondrocytes; Crotonates; Cytokines; Dose-Response Relationship, Drug; Fibroblasts; Humans; Hydroxybutyrates; Indomethacin; Interleukin-1; Isoxazoles; Leflunomide; Nitriles; Receptors, Interleukin-1; Synovial Membrane; Toluidines; Tumor Necrosis Factor-alpha | 2004 |
Leflunomide attenuates hepatocyte injury by inhibiting Kupffer cells.
Topics: Aniline Compounds; Animals; Cell Communication; Cells, Cultured; Crotonates; Hepatitis; Hepatocytes; Hydroxybutyrates; Immunosuppressive Agents; Interleukin-1; Isoxazoles; Kupffer Cells; Leflunomide; Lipopolysaccharides; Male; Nitriles; Rats; Rats, Sprague-Dawley; Toluidines; Tumor Necrosis Factor-alpha | 2004 |
The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage.
Topics: Aniline Compounds; Animals; Binding Sites; Bone Resorption; Carrier Proteins; Cell Differentiation; Cell Lineage; Cells, Cultured; Crotonates; Electrophoretic Mobility Shift Assay; Hydroxybutyrates; Isoxazoles; Leflunomide; Membrane Glycoproteins; Mice; NF-kappa B; Nitriles; Osteoclasts; Phosphorylation; Phosphotyrosine; Proto-Oncogene Proteins pp60(c-src); Pyrimidines; Rabbits; RANK Ligand; Receptor Activator of Nuclear Factor-kappa B; Toluidines | 2004 |
Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis.
Topics: Aged; Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Crotonates; Drug Monitoring; Female; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Male; Middle Aged; Nitriles; Prodrugs; ROC Curve; Severity of Illness Index; Toluidines; Treatment Outcome | 2005 |
A rapid and simple determination of A77 1726 in human serum by high-performance liquid chromatography and its application for optimization of leflunomide therapy.
Topics: Aniline Compounds; Antirheumatic Agents; Buffers; Chromatography, High Pressure Liquid; Crotonates; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Nitriles; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Time Factors; Toluidines | 2004 |
A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells.
Topics: Aniline Compounds; Animals; Cell Communication; Cell Survival; Cells, Cultured; Coculture Techniques; Crotonates; Hepatitis; Hepatocytes; Hydroxybutyrates; Immunosuppressive Agents; Interleukin-1; Isoxazoles; Kupffer Cells; Leflunomide; Lipopolysaccharides; Male; Nitriles; Rats; Rats, Sprague-Dawley; RNA, Messenger; Toluidines; Tumor Necrosis Factor-alpha | 2004 |
[The active metabolite of leflunomide A771726 inhibits proliferation and collagen synthesis of hepatic stellate cell].
Topics: Aniline Compounds; Animals; Carbon Tetrachloride; Cell Division; Cells, Cultured; Collagen Type I; Crotonates; Hepatocytes; Hydroxybutyrates; Immunosuppressive Agents; Interleukin-1; Isoxazoles; Kupffer Cells; Leflunomide; Male; Nitriles; Rats; Rats, Sprague-Dawley; Toluidines; Transforming Growth Factor beta | 2004 |
Leflunomide for polyomavirus type BK nephropathy.
Topics: Aniline Compounds; Antiviral Agents; BK Virus; Crotonates; Humans; Hydroxybutyrates; Isoxazoles; Kidney Diseases; Kidney Transplantation; Leflunomide; Nitriles; Polyomavirus Infections; Toluidines; Tumor Virus Infections | 2005 |
The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function.
Topics: Aniline Compounds; Cell Differentiation; Cells, Cultured; Crotonates; Dendritic Cells; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Leukocytes, Mononuclear; Nitriles; Toluidines | 2005 |
Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes.
Topics: Active Transport, Cell Nucleus; Aniline Compounds; Anti-Inflammatory Agents; Apoptosis; Arthritis, Rheumatoid; Cells, Cultured; Crotonates; Cyclooxygenase 2; Cytokines; Dinoprostone; DNA Fragmentation; Dose-Response Relationship, Drug; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Hydroxybutyrates; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-10; Interleukin-11; Interleukin-8; Isoxazoles; Leflunomide; MAP Kinase Signaling System; Membrane Proteins; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; NF-kappa B; Nitriles; p38 Mitogen-Activated Protein Kinases; Prostaglandin-Endoperoxide Synthases; Receptors, Tumor Necrosis Factor, Type I; Sialoglycoproteins; Synovial Fluid; Time Factors; Toluidines; Trypsin | 2005 |
Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis.
Topics: Adjuvants, Immunologic; Adult; Aged; Aniline Compounds; Arthritis, Rheumatoid; Cross-Sectional Studies; Crotonates; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Male; Middle Aged; Nitriles; Toluidines | 2005 |
Disruption of the interaction of T cells with antigen-presenting cells by the active leflunomide metabolite teriflunomide: involvement of impaired integrin activation and immunologic synapse formation.
Topics: Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Antigen-Presenting Cells; Cell Adhesion; Crotonates; Dose-Response Relationship, Drug; Humans; Hydroxybutyrates; Immunosuppression Therapy; Integrins; Intercellular Adhesion Molecule-1; Isoxazoles; Jurkat Cells; Leflunomide; Nitriles; Receptor-CD3 Complex, Antigen, T-Cell; Signal Transduction; Superantigens; T-Lymphocytes; Toluidines | 2005 |
Treatment of renal allograft polyoma BK virus infection with leflunomide.
Topics: Aniline Compounds; BK Virus; Blood; Cells, Cultured; Creatinine; Crotonates; Female; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Kidney; Kidney Transplantation; Leflunomide; Male; Middle Aged; Nitriles; Polyomavirus Infections; Renal Insufficiency; Tacrolimus; Toluidines; Urine; Virus Replication | 2006 |
Leflunomide or A77 1726 protect from acetaminophen-induced cell injury through inhibition of JNK-mediated mitochondrial permeability transition in immortalized human hepatocytes.
Topics: Acetaminophen; Aniline Compounds; Anthracenes; Antirheumatic Agents; Caspase 3; Cell Death; Cell Line; Crotonates; Cytochromes c; Dose-Response Relationship, Drug; Enzyme Activation; Glutathione; Hepatocytes; Humans; Hydroxybutyrates; Isoxazoles; JNK Mitogen-Activated Protein Kinases; Leflunomide; Mitochondria, Liver; Mitochondrial Membrane Transport Proteins; Mitochondrial Permeability Transition Pore; Mitogen-Activated Protein Kinase 8; Mitogen-Activated Protein Kinase 9; Nitriles; Phosphorylation; Protein Carbonylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Toluidines | 2006 |
The active metabolite of leflunomide, A77 1726, increases proliferation of human synovial fibroblasts in presence of IL-1beta and TNF-alpha.
Topics: Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Cell Proliferation; Cells, Cultured; Crotonates; Drug Synergism; Enzyme Inhibitors; Fibroblasts; Humans; Hydroxybutyrates; Interleukin-1beta; Isoxazoles; Jurkat Cells; Leflunomide; Nitriles; Prostaglandin-Endoperoxide Synthases; Protein-Tyrosine Kinases; Synovial Membrane; Toluidines; Tumor Necrosis Factor-alpha; Uridine | 2006 |
Suppressive effects of leflunomide on leptin-induced collagen I production involved in hepatic stellate cell proliferation.
Topics: Aniline Compounds; Animals; Cell Cycle; Cell Proliferation; Cells, Cultured; Collagen Type I; Crotonates; Culture Media, Conditioned; Cyclin D; Cyclins; Cytokines; Extracellular Signal-Regulated MAP Kinases; Fibroblasts; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Kupffer Cells; Leflunomide; Leptin; Liver; Macrophage Activation; Nitriles; Phosphorylation; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; STAT3 Transcription Factor; Toluidines | 2007 |
Post-infection A77-1726 blocks pathophysiologic sequelae of respiratory syncytial virus infection.
Topics: Administration, Intranasal; Airway Resistance; Aniline Compounds; Animals; Antiviral Agents; Bronchoalveolar Lavage Fluid; Cell Count; Chemokines; Crotonates; Dimethyl Sulfoxide; DNA; Drug Administration Schedule; Extravascular Lung Water; Hydroxybutyrates; Isoxazoles; Leflunomide; Lung; Mice; Mice, Inbred BALB C; Nitriles; Oxygen; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Toluidines; Virus Replication | 2007 |
In vitro effects of the active metabolite of leflunomide, A77 1726, on feline herpesvirus-1.
Topics: Aniline Compounds; Animals; Antiviral Agents; Apoptosis; Cat Diseases; Cats; Cell Line; Cell Survival; Crotonates; DNA, Viral; Herpesviridae; Herpesviridae Infections; Hydroxybutyrates; Isoxazoles; Leflunomide; Microscopy, Electron, Transmission; Mitochondria; Nitriles; Polymerase Chain Reaction; Statistics, Nonparametric; Toluidines; Viral Load; Virus Replication | 2007 |
The immunomodulatory drug Leflunomide inhibits cell cycle progression of B-CLL cells.
Topics: Apoptosis; B-Lymphocytes; Crotonates; Cyclin A; Cyclin D3; Cyclin-Dependent Kinase 2; Cyclins; Dihydroorotate Dehydrogenase; DNA Replication; Drug Screening Assays, Antitumor; G1 Phase; Humans; Hydroxybutyrates; Immunologic Factors; Isoxazoles; Leflunomide; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasm Proteins; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; Phosphorylation; Prodrugs; Protein Processing, Post-Translational; Receptors, Immunologic; Receptors, Prostaglandin; Retinoblastoma Protein; Toluidines; Tumor Cells, Cultured; ZAP-70 Protein-Tyrosine Kinase | 2008 |
Leflunomide inhibits PDK1/Akt pathway and induces apoptosis of human mast cells.
Topics: Aniline Compounds; Apoptosis; Arthritis, Rheumatoid; Cell Survival; Cells, Cultured; Chronic Disease; Crotonates; Dihydroorotate Dehydrogenase; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; Humans; Hydroxybutyrates; Immunosuppressive Agents; Inflammation Mediators; Isoxazoles; Leflunomide; Mast Cells; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Pyruvate Dehydrogenase Acetyl-Transferring Kinase; Signal Transduction; Synovial Membrane; Synovitis; Toluidines; Uridine | 2007 |
Suppressive effects of leflunomide on leptin-induced TIMP-1 production involves on hepatic stellate cell proliferation and apoptosis.
Topics: Aniline Compounds; Animals; Apoptosis; Cell Proliferation; Cells, Cultured; Crotonates; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Janus Kinases; Leflunomide; Leptin; Liver; Mitogen-Activated Protein Kinases; Nitriles; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Signal Transduction; STAT Transcription Factors; Tissue Inhibitor of Metalloproteinase-1; Toluidines | 2008 |
Suppressive effect of leflunomide on rat hepatic stellate cell proliferation involves on PDGF-BB-elicited activation of three mitogen-activated protein kinases.
Topics: Aniline Compounds; Animals; Becaplermin; Cell Proliferation; Cells, Cultured; Crotonates; Culture Media, Conditioned; Enzyme Activation; Enzyme Inhibitors; Hepatocytes; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Kupffer Cells; Leflunomide; Mitogen-Activated Protein Kinases; Nitriles; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Rats; Rats, Sprague-Dawley; Receptor, Platelet-Derived Growth Factor beta; Toluidines | 2008 |
Leflunomide and its metabolite A771726 are high affinity substrates of BCRP: implications for drug resistance.
Topics: Adenosine Triphosphatases; Aniline Compounds; Antirheumatic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Cell Line; Cell Survival; Crotonates; Drug Resistance; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Neoplasm Proteins; Nitriles; Toluidines | 2009 |
The active metabolite of leflunomide A771726 inhibits corneal neovascularization.
Topics: Aniline Compounds; Animals; Cell Nucleus; Cell Proliferation; Corneal Neovascularization; Crotonates; Disease Models, Animal; Humans; Hydrogen-Ion Concentration; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Nitriles; Proliferating Cell Nuclear Antigen; Rats; Rats, Sprague-Dawley; Tetrazolium Salts; Thiazoles; Time Factors; Toluidines; Umbilical Veins | 2008 |
The active metabolite of leflunomide, A77 1726, protects rat hepatocytes against bile acid-induced apoptosis.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Bile Acids and Salts; Crotonates; Glycochenodeoxycholic Acid; Hepatocytes; Hydroxybutyrates; In Vitro Techniques; Isoxazoles; Leflunomide; Male; MAP Kinase Signaling System; Necrosis; NF-kappa B; Nitriles; Oxidative Stress; Rats; Rats, Wistar; Toluidines; Tumor Necrosis Factor-alpha | 2008 |
Suppression of immunoglobulin production by a novel dihydroorotate dehydrogenase inhibitor, S-2678.
Topics: Administration, Oral; Aniline Compounds; Animals; Antibody Formation; B-Lymphocytes; Biphenyl Compounds; Cell Proliferation; Crotonates; Dihydroorotate Dehydrogenase; Enzyme Inhibitors; Female; Humans; Hydroxybutyrates; Immunoglobulin Heavy Chains; Immunoglobulins; Isoxazoles; Leflunomide; Leukocytes, Mononuclear; Mice; Mice, Inbred BALB C; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; Pyridines; Toluidines | 2008 |
In vitro metabolism of leflunomide by mouse and human liver microsomes.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, Liquid; Crotonates; Humans; Hydroxybutyrates; Hydroxylation; Isoxazoles; Leflunomide; Male; Mice; Microsomes, Liver; Nitriles; Toluidines | 2007 |
Oxidative bioactivation and toxicity of leflunomide in immortalized human hepatocytes and kinetics of the non-enzymatic conversion to its major metabolite, A77 1726.
Topics: Aniline Compounds; Antirheumatic Agents; Cells, Cultured; Chromatography, Liquid; Crotonates; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Half-Life; Hepatocytes; Humans; Hydroxybutyrates; Isoxazoles; L-Lactate Dehydrogenase; Leflunomide; Nitriles; Oxidation-Reduction; Tandem Mass Spectrometry; Time Factors; Toluidines; Toxicity Tests | 2008 |
Sensitization of human hepatic stellate cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by leflunomide.
Topics: Aniline Compounds; Apoptosis; Blotting, Western; Caspases; Cell Line; Crotonates; Hepatic Stellate Cells; Humans; Hydroxybutyrates; Isoxazoles; JNK Mitogen-Activated Protein Kinases; Leflunomide; Liver Cirrhosis; NF-kappa B; Nitriles; Receptors, TNF-Related Apoptosis-Inducing Ligand; Receptors, Tumor Necrosis Factor; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; TNF-Related Apoptosis-Inducing Ligand; Toluidines | 2009 |
Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; Aryl Hydrocarbon Hydroxylases; Crotonates; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Female; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Male; Middle Aged; Nitriles; Polymorphism, Genetic; Synovial Membrane; Toluidines | 2009 |
Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis.
Topics: Aged; Aniline Compounds; Antirheumatic Agents; Arthritis, Rheumatoid; C-Reactive Protein; Crotonates; Female; Humans; Hydroxybutyrates; Hypoxia; Isoxazoles; Japan; Leflunomide; Lung Diseases, Interstitial; Lung Injury; Male; Middle Aged; Nitriles; Product Surveillance, Postmarketing; Prognosis; Respiration, Artificial; Risk Factors; Serum Albumin; Toluidines | 2009 |
Leflunomide inhibition of BK virus replication in renal tubular epithelial cells.
Topics: Aniline Compounds; Antiviral Agents; BK Virus; Cells, Cultured; Crotonates; DNA Replication; Epithelial Cells; Humans; Hydroxybutyrates; Isoxazoles; Kidney Tubules; Leflunomide; Microscopy, Electron, Transmission; Nitriles; Toluidines; Viral Load; Viral Structural Proteins; Virus Assembly; Virus Replication | 2010 |
Identification of a novel Raf-1 pathway activator that inhibits gastrointestinal carcinoid cell growth.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromogranin A; Crotonates; Enzyme Activation; Gastrointestinal Neoplasms; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Mice; Neoplasm Transplantation; Nitriles; Proto-Oncogene Proteins c-raf; Serotonin; Toluidines | 2010 |
A rapid and simple high-performance liquid chromatography assay for the leflunomide metabolite, teriflunomide (A77 1726), in renal transplant recipients.
Topics: BK Virus; Chromatography, High Pressure Liquid; Crotonates; Drug Monitoring; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Kidney Transplantation; Leflunomide; Mass Spectrometry; Nitriles; Polyomavirus Infections; Regression Analysis; Toluidines | 2010 |
Estrogens interfere with leflunomide modulation of cytokine production by human activated monocytes.
Topics: Aniline Compounds; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cell Differentiation; Cells, Cultured; Crotonates; Cytokines; Drug Interactions; Estradiol; Estrogens; Humans; Hydroxybutyrates; Immunohistochemistry; Interleukin-6; Isoxazoles; Leflunomide; Macrophages; Monocytes; Nitriles; Reverse Transcriptase Polymerase Chain Reaction; Tetradecanoylphorbol Acetate; Toluidines; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2010 |
Chromatographic separation and sensitive determination of teriflunomide, an active metabolite of leflunomide in human plasma by liquid chromatography-tandem mass spectrometry.
Topics: Acetates; Adult; Chromatography, Liquid; Crotonates; Drug Stability; High-Throughput Screening Assays; Humans; Hydroxybutyrates; Isoxazoles; Least-Squares Analysis; Leflunomide; Male; Middle Aged; Nitriles; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Therapeutic Equivalency; Toluidines | 2010 |
Effect of ABCG2 genotypes on the pharmacokinetics of A771726, an active metabolite of prodrug leflunomide, and association of A771726 exposure with serum uric acid level.
Topics: Aniline Compounds; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Crotonates; Genotype; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Neoplasm Proteins; Nitriles; Polymorphism, Single Nucleotide; Prodrugs; Protein Transport; Toluidines; Uric Acid | 2011 |
Hepatic cytochrome P450s attenuate the cytotoxicity induced by leflunomide and its active metabolite A77 1726 in primary cultured rat hepatocytes.
Topics: Aniline Compounds; Animals; Benzoflavones; Biomarkers; Cell Survival; Cells, Cultured; Crotonates; Cytochrome P-450 Enzyme System; Hepatocytes; Hydroxybutyrates; Inactivation, Metabolic; Isoxazoles; Ketoconazole; Leflunomide; Liver; Male; Nitriles; Primary Cell Culture; Proadifen; Rats; Rats, Sprague-Dawley; Ticlopidine; Toluidines; Triazoles | 2011 |
[Inhibition of leflunomide active metabolite A771726 on high glucose-induced podocyte apoptosis].
Topics: Aniline Compounds; Apoptosis; Cells, Cultured; Crotonates; Glucose; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Nitriles; p38 Mitogen-Activated Protein Kinases; Podocytes; Signal Transduction; Toluidines | 2011 |
Inhibiting effects of Leflunomide metabolite on overexpression of CD147, MMP-2 and MMP-9 in PMA differentiated THP-1 cells.
Topics: Aniline Compounds; Basigin; Cell Differentiation; Cell Line; Collagenases; Crotonates; Gelatin; Gene Expression Regulation; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Monocytes; Nitriles; RNA, Messenger; Tetradecanoylphorbol Acetate; Toluidines | 2011 |
Leflunomide pharmacokinetics after single oral administration to dogs.
Topics: Administration, Oral; Animals; Chromatography, High Pressure Liquid; Crotonates; Dogs; Drug Administration Schedule; Female; Half-Life; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Linear Models; Nitriles; Toluidines | 2011 |
An aggregation sensing reporter identifies leflunomide and teriflunomide as polyglutamine aggregate inhibitors.
Topics: Amino Acid Sequence; Cell Line; Crotonates; Drug Evaluation, Preclinical; HEK293 Cells; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Luciferases, Firefly; Molecular Sequence Data; Nerve Tissue Proteins; Nitriles; Peptides; Pyrimidines; Recombinant Fusion Proteins; Toluidines | 2012 |
Leflunomide induces apoptosis in fludarabine-resistant and clinically refractory CLL cells.
Topics: Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Agents; Apoptosis; CD40 Ligand; Cell Proliferation; Crotonates; Drug Resistance, Neoplasm; Humans; Hydroxybutyrates; Interleukin-4; Isoxazoles; Janus Kinases; Leflunomide; Leukemia, Lymphocytic, Chronic, B-Cell; Middle Aged; Nitriles; Signal Transduction; STAT Transcription Factors; Toluidines; Tumor Cells, Cultured; Vidarabine | 2012 |
Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection.
Topics: Adult; Aniline Compounds; Antiviral Agents; Biotransformation; BK Virus; Chi-Square Distribution; Crotonates; Drug Monitoring; Female; Humans; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Kidney Transplantation; Leflunomide; Male; Middle Aged; Multivariate Analysis; Mycophenolic Acid; Nitriles; Polymerase Chain Reaction; Polyomavirus Infections; Proportional Hazards Models; Retrospective Studies; South Carolina; Toluidines; Treatment Outcome; Tumor Virus Infections; Viral Load | 2012 |
Falsely decreased ionized calcium results due to analytical interference by teriflunomide, the active metabolite of leflunomide (Arava®).
Topics: Artifacts; Blood Chemical Analysis; Calcium; Crotonates; False Positive Reactions; Humans; Hydroxybutyrates; Isoxazoles; Kidney Transplantation; Leflunomide; Nitriles; Toluidines | 2012 |
The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.
Topics: Aniline Compounds; Cell Line, Tumor; Cell Proliferation; Crotonates; Cyclin-Dependent Kinase Inhibitor p21; Dihydroorotate Dehydrogenase; Fluoresceins; Gene Knockdown Techniques; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Melanoma; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; Proto-Oncogene Proteins c-myc; Receptors, Aryl Hydrocarbon; Signal Transduction; Succinimides; Toluidines; Uridine | 2012 |
Leflunomide in dialysis patients with rheumatoid arthritis--a pharmacokinetic study.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Crotonates; Female; Humans; Hydroxybutyrates; Isoxazoles; Kidney Failure, Chronic; Leflunomide; Male; Middle Aged; Models, Biological; Nitriles; Renal Dialysis; Retrospective Studies; Toluidines | 2013 |
In-vitro immunosuppression of canine T-lymphocyte-specific proliferation with dexamethasone, cyclosporine, and the active metabolites of azathioprine and leflunomide in a flow-cytometric assay.
Topics: Aniline Compounds; Animals; Azathioprine; Cell Proliferation; Crotonates; Cyclosporine; Dexamethasone; Dogs; Flow Cytometry; Hydroxybutyrates; Immunosuppressive Agents; Isoxazoles; Leflunomide; Mercaptopurine; Nitriles; T-Lymphocytes; Toluidines | 2014 |
Inhibition of p70 S6 kinase (S6K1) activity by A77 1726 and its effect on cell proliferation and cell cycle progress.
Topics: Aniline Compounds; Butadienes; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Chromones; Crotonates; Feedback, Physiological; Gene Knockdown Techniques; Humans; Hydroxybutyrates; Imidazoles; Isoxazoles; Leflunomide; MAP Kinase Signaling System; Morpholines; Nitriles; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Pyrazines; Receptor, IGF Type 1; Ribosomal Protein S6 Kinases, 70-kDa; Toluidines | 2014 |
On the interactions of leflunomide and teriflunomide within receptor cavity--NMR studies and energy calculations.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Binding Sites; Crotonates; Dihydroorotate Dehydrogenase; Energy Metabolism; Humans; Hydrogen Bonding; Hydroxybutyrates; Isoxazoles; Leflunomide; Magnetic Resonance Spectroscopy; Models, Molecular; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; Toluidines | 2015 |
Teriflunomide (AUBAGIO). Multiple sclerosis: just a metabolite of leflunomide.
Topics: Animals; Crotonates; Drug Interactions; Female; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Multiple Sclerosis; Nitriles; Pregnancy; Toluidines | 2015 |
Topical delivery of leflunomide for rheumatoid arthritis treatment: evaluation of local tissue deposition of teriflunomide and its anti-inflammatory effects in an arthritis rat model.
Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Arthritis, Rheumatoid; Crotonates; Drug Delivery Systems; Guinea Pigs; Hydroxybutyrates; Isoxazoles; Leflunomide; Mice; Mice, Hairless; Mice, Inbred BALB C; Nitriles; Rats; Rats, Sprague-Dawley; Skin Absorption; Swine; Swine, Miniature; Tissue Distribution; Toluidines; Transdermal Patch | 2016 |
Effect of Leflunomide on the Abnormal Expression of Lipid Rafts and F-Actin in B Lymphocytes from Patients with Systemic Lupus Erythematosus.
Topics: Actins; Adult; Aniline Compounds; Antigens, CD; B-Lymphocytes; Case-Control Studies; Crotonates; Female; Humans; Hydroxybutyrates; Immunoglobulin D; Immunosuppressive Agents; Isoxazoles; Leflunomide; Lupus Erythematosus, Systemic; Male; Membrane Microdomains; Nitriles; Toluidines | 2015 |
Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Crotonates; Cytochrome P-450 CYP1A2; Female; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Male; Middle Aged; Nitriles; Polymorphism, Single Nucleotide; Toluidines | 2016 |
Quantitation of Teriflunomide in Human Serum/Plasma Across a 40,000-Fold Concentration Range by LC/MS/MS.
Topics: Arthritis, Rheumatoid; Chromatography, Liquid; Crotonates; Dihydroorotate Dehydrogenase; Drug Monitoring; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Limit of Detection; Nitriles; Oxidoreductases Acting on CH-CH Group Donors; Prodrugs; Tandem Mass Spectrometry; Toluidines | 2016 |
Inhibition of hepatic cytochrome P450 enzymes and sodium/bile acid cotransporter exacerbates leflunomide-induced hepatotoxicity.
Topics: Animals; Antirheumatic Agents; Cells, Cultured; Chemical and Drug Induced Liver Injury; Crotonates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Female; HEK293 Cells; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Liver; Male; Mice, Inbred C57BL; Nitriles; Organic Anion Transporters, Sodium-Dependent; Rats, Sprague-Dawley; Symporters; Toluidines | 2016 |
Detection of in Vitro Metabolite Formation of Leflunomide: A Fluorescence Dynamics and Electronic Structure Study.
Topics: Antirheumatic Agents; Crotonates; Fluorescence; Hydroxybutyrates; In Vitro Techniques; Isoxazoles; Leflunomide; Models, Molecular; Nitriles; Protons; Quantum Theory; Spectrometry, Fluorescence; Toluidines | 2016 |
Novel electrospun nanofibrous matrices prepared from poly(lactic acid)/poly(butylene adipate) blends for controlled release formulations of an anti-rheumatoid agent.
Topics: Antirheumatic Agents; Biocompatible Materials; Butylene Glycols; Cell Line; Crotonates; Delayed-Action Preparations; Drug Liberation; Electrochemical Techniques; Fibroblasts; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Linear Models; Microscopy, Electron, Scanning; Models, Chemical; Nanofibers; Neural Networks, Computer; Nitriles; Polyesters; Polymers; Toluidines | 2016 |
The active metabolite of leflunomide, A77 1726, attenuates inflammatory arthritis in mice with spontaneous arthritis via induction of heme oxygenase-1.
Topics: Aniline Compounds; Animals; Anti-Inflammatory Agents; Arthritis, Experimental; Arthritis, Rheumatoid; Cell Differentiation; Crotonates; Forkhead Transcription Factors; Heme Oxygenase-1; Humans; Hydroxybutyrates; Inflammation; Isoxazoles; Jurkat Cells; Leflunomide; Mice, Inbred BALB C; Mice, Inbred C57BL; NF-E2-Related Factor 2; Nitric Oxide Synthase Type II; Nitriles; Oxidative Stress; Signal Transduction; Spleen; Th17 Cells; Toluidines; Tyrosine | 2017 |
Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)- induced lymphoproliferative disease and lytic viral replication.
Topics: Animals; Apoptosis; B-Lymphocytes; Cell Line, Transformed; Cell Proliferation; Crotonates; Cyclin E; Disease Models, Animal; Epstein-Barr Virus Infections; Gene Expression Regulation; Gene Expression Regulation, Viral; Genes, myc; Herpesvirus 4, Human; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Lymphoproliferative Disorders; Mice; NF-kappa B; Nitriles; Toluidines; Virus Activation; Virus Latency; Virus Replication; Xenograft Model Antitumor Assays | 2017 |
Anti-inflammatory drug, leflunomide and its metabolite teriflunomide inhibit NSCLC proliferation in vivo and in vitro.
Topics: Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Crotonates; Female; Humans; Hydroxybutyrates; Isoxazoles; Leflunomide; Mice, Nude; Nitriles; Toluidines; Xenograft Model Antitumor Assays | 2018 |
Therapeutic drug monitoring of teriflunomide: do plasma concentrations predict response to leflunomide in patients with rheumatoid arthritis?
Topics: Arthritis, Rheumatoid; Drug Monitoring; Humans; Isoxazoles; Leflunomide; Treatment Outcome | 2023 |